



(51) International Patent Classification:

C07K 14/47 (2006.01) C12N 7/01 (2006.01)
C07K 14/52 (2006.01) C12N 15/09 (2006.01)

(21) International Application Number:

PCT/US2018/016912

(22) International Filing Date:

05 February 2018 (05.02.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/454,526 03 February 2017 (03.02.2017) US

(71) Applicant: UNIVERSITY OF PITTSBURGH-OF THE
COMMONWEALTH SYSTEM OF HIGHER EDU-
CATION [US/US]; 1st Floor Gardner Steel Conference
Center, 130 Thackeray Avenue, Pittsburgh, PA 15260 (US).

(72) Inventors: GUO, Zong, Sheng; 2446 Wedgewood Drive,
Wexford, PA 15090 (US). BARTLETT, David; 504 Old
Orchard Trail, Pittsburgh, PA 15238 (US). LIU, Zuqiang;
9920 Belton Circle, Apt. 204, Wexford, PA 15090 (US).
FEIST, Mathilde; c/o University Of Pittsburgh, 1st Floor
Gardner Steel Conference Center, 130 Thackeray Avenue,
Pittsburgh, PA 15260 (US).

(74) Agent: KOLE, Lisa, B. et al.; Baker Botts L.L.P., 30 Rock-
efeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ONCOLYTIC VIRUS THERAPY

A. Experimental scheme




FIG. 1A

(57) Abstract: The presently disclosed subject matter relates to tumor infil-
trated T cells induced by oncolytic virus ("OV-induced T cells"), methods of
making and using said OV-induced T cells for an adoptive T-cell therapy.
The presently disclosed subject matter further relates to oncolytic viruses and
armed oncolytic viruses, methods of making and using said oncolytic viruses,
as well as pharmaceutical compositions and kits comprising said oncolytic
viruses.



ONCOLYTIC VIRUS THERAPY

PRIORITY CLAIM

This patent application claims priority to United States Provisional Application
5 No. 62/454,526, filed February 3, 2017, the contents of which are hereby incorporated by
reference in their entirety herein.

GRANT INFORMATION

10 None applicable.

1. INTRODUCTION

The presently disclosed subject matter relates to oncolytic viruses, armed
oncolytic viruses encoding, in an expressible form, an immunomodulator molecule, and
15 to compositions of, and methods of making and using said oncolytic viruses. The
presently disclosed subject matter also relates to tumor infiltrated T cells - induced by
oncolytic virus ("OV-induced T cells"), and to methods of making and using said OV-
induced T cells for adoptive T-cell therapy.

20 2. BACKGROUND OF THE INVENTION

Oncolytic viruses, which selectively replicate in and kill cancer cells, exert their
anti-cancer effects through a number of modalities (Bartlett DL et al., 2013, Molecular
Cancer 12:103-120). The first, as their name implies, is cell lysis, which can be achieved
through apoptosis, necrosis, pyroptosis, autophagy, or a combination of these (Guo ZS et
25 al., 2014, Front Oncol 4:74). Further, oncolytic viruses can attack a cancer's blood
supply, leading to apoptosis and necrosis of infected as well as non-infected cells.
Finally, oncolytic viruses induce immunogenic cell death (ICD) of cancer cells, release
and present danger signal molecules (signal 0), along with inflammatory cytokines, and
cross-present tumor-associated antigens (TAAs) to naïve T cells, leading to elicitation of
30 anti-tumor immunity (Guo ZS et al., 2014, Front Oncol 4:74). The potent oncolytic
viruses not only elicit potent and systemic adaptive antitumor immunity, but also promote
the trafficking of tumor-specific CD8⁺ T cells into the tumor tissues (Bartlett DL et al.,
2013, Mol Cancer 12:103; Guo ZS et al., 2017, 8:555).

This immune response against the cancer is not restricted to infected cancer cells,
35 but extends to metastatic lesions. The approval of the first-in-class drug, T-VEC, by the
FDA to treat advanced melanoma in 2015, showcased the potential of this type of novel

treatment for cancer (Andtbacka RH et al., 2015, J Clin Oncol 33:2780-8). Despite their advantages, oncolytic viruses have, to date, faced challenges, including gaining access to cancer cells within tumor nodules in adequate numbers, anti-virus immune responses, and a highly immunosuppressive tumor environment (Zou W., 2005, Nat Rev Cancer 5:263-74). In addition, infiltration of tumor-specific T cells, if they indeed are generated and activated, encounter hurdles, the major one being to infiltrate to tumor tissue where they exert their cytotoxicity to cancer cells and associated stromal cells.

These challenges would be desirably improved by agents that modulate the immune system - for example agents that increase anti-cancer immunity and/or decrease anti-virus immunity. However, agents capable of such immunomodulation - cytokines and the like - can have profound, potentially dangerous effects on a treated subject when systemically dispersed.

3. SUMMARY OF THE INVENTION

The presently disclosed subject matter relates to compositions and methods which promote anti-cancer immunity in the context on oncolytic virus therapy. In certain embodiments, adoptive T cell therapy is used as part of an anti-cancer regimen employing oncolytic virus to promote an immune response against cancer cells, and the oncolytic virus is optionally administered with an immunomodulator. In certain embodiments, the immunomodulator is linked to the oncolytic virus.

In certain embodiments, the presently disclosed subject matter provides a method for generating tumor infiltrating oncolytic-virus induced T cells, comprising:

- (a) administering, to a subject having a cancer, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer;
- (b) isolating the tumor-infiltrated T cells from the cancer of the subject; and
- (c) expanding the tumor-infiltrated T cells *ex vivo*.

In certain embodiments, the presently disclosed subject matter provides a method of treating a subject suffering from cancer, comprising administering to the subject one or more tumor infiltrating oncolytic-virus induced T cells disclosed herein.

In certain embodiments, the presently disclosed subject matter provides a method of treating a subject suffering from cancer, comprising:

- (a) administering, to the subject, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer;
- (b) isolating the tumor-infiltrated T cells from the cancer of the subject;

(c) expanding the tumor-infiltrated T cells *ex vivo*; and

(d) transferring the expanded tumor-infiltrated T cells to the subject suffering from cancer.

In certain embodiments, the oncolytic virus is a vaccinia virus. In certain
5 embodiments, the oncolytic virus is a recombinant vaccinia virus with an inactivating
mutation of its thymidine kinase gene, vaccinia growth factor gene, or both. In certain
embodiments, the oncolytic virus is a herpes simplex virus. In certain embodiments, the
oncolytic virus is an adenovirus.

In certain embodiments, the tumor-infiltrated T cells are expanded *ex vivo* in the
10 presence of IL-2 and IL-7. In certain embodiments, expanding the tumor-infiltrated T
cells comprises co-culturing the tumor-infiltrated T cells with dendritic cells and cancer
cells. In certain embodiments, expanding the tumor-infiltrated T cells comprises
culturing the tumor-infiltrated T cells with cytokines and/or agents. In certain
embodiments, the cytokines and/or the agents comprise one or more of IL-1, IL-2, IL-3,
15 IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21,
IL-23, IL-24, IL-27, IFN-alpha, IFN-alpha2, IFN-beta, or IFN-gamma, TNF-alpha, TNF-
beta, and GM-CSF. In certain embodiments, expanding the tumor-infiltrated T cells
comprises culturing the tumor-infiltrated T cells with IL-2, IL-7, and/or GSK3b.

In certain embodiments, the subject suffering from cancer is treated with a cancer
20 therapy before transferring the tumor-infiltrated T cells to the subject suffering from
cancer. In certain embodiments, the subject suffering from cancer is further treated with a
cancer therapy. In certain embodiments, the subject suffering from cancer is further with
one or more exogenous cytokine and/or agent. In certain embodiments, the subject
suffering from cancer is further provided with exogenous IL-2, after transferring the
25 tumor-infiltrated T cells.

In certain embodiments, the tumor-infiltrated cells are transferred intraperitoneally
or intratumorally. In certain embodiments, the presently disclosed subject matter is
directed to the use of an oncolytic virus for treating a subject having cancer.

In certain embodiments, the presently disclosed subject matter is directed to the
30 use of an oncolytic virus for generating tumor infiltrating oncolytic-virus induced T cells.
In certain embodiments, the presently disclosed subject matter is directed to the use of
tumor infiltrating oncolytic-virus induced T cells for treating a subject having cancer.

In certain embodiments, the tumor infiltrating oncolytic-virus induced T cells are
generated by a method comprising:

- (a) administering, to a subject having a cancer, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer;
- (b) isolating the tumor-infiltrated T cells from the cancer of the subject; and
- (c) expanding the tumor-infiltrated T cells *ex vivo*.

5 In various embodiments, the presently disclosed subject matter provides for the oncolytic viruses, the induced tumor-infiltrated T cells, therapeutic compositions comprising said viruses and T cells, and methods of treating subjects suffering from conditions that would benefit from immunomodulation, including patients suffering from various cancers.

10 In certain embodiments, the presently disclosed subject matter provides an oncolytic virus encoding a membrane-associated protein comprising an immunomodulator molecule linked to an anchoring peptide. In certain embodiments, the presently disclosed subject matter provides an oncolytic virus comprising, in its genome, a nucleic acid encoding a membrane-associated protein comprising an immunomodulator
15 molecule linked to an anchoring peptide.

 In certain embodiments, the oncolytic virus is a vaccinia virus. In certain embodiments, the oncolytic virus is a recombinant vaccinia virus with an inactivating mutation of its thymidine kinase gene, vaccinia growth factor gene, or both. In certain embodiments, the nucleic acid encoding the immunomodulatory molecule linked to the
20 anchoring peptide is operably linked to the p7.5 e/l promoter.

 In certain embodiments, the anchoring peptide comprises a GPI-anchor acceptor peptide or a PD-L1 transmembrane domain. In certain embodiments, the immunomodulator molecule is joined to the anchoring peptide via a linker peptide. In certain embodiments, the linker is a flexible linker or a rigid linker. In certain
25 embodiments, the immunomodulator molecule is interleukin-2 and/or interferon-gamma, and/or tumor necrosis factor-alpha.

 In certain embodiments, an oncolytic virus is administered as a therapeutic composition. In certain embodiments, the presently disclosed subject matter provides a therapeutic composition comprising an oncolytic virus together with a physiologic buffer.
30 In certain embodiments, the therapeutic composition is in lyophilized form. In certain embodiments, the presently disclosed subject matter provides a syringe comprising an effective amount of the therapeutic composition.

 In certain embodiments, the presently disclosed subject matter provides a method of treating a subject suffering from a cancer, comprising administering, to the subject, an

effective amount of an oncolytic virus encoding an immunomodulator molecule. In certain embodiments, the immunomodulator molecule is interleukin-2. In certain embodiments, the cancer is locally invasive. In certain embodiments, the cancer is metastatic. In certain embodiments, the oncolytic virus is administered intratumorally. In certain embodiments, a therapeutically effective amount of an immunomodulatory agent is further administered to the subject suffering from a cancer. In certain embodiments, the immunomodulatory agent is an anti-PD-1 or an anti-PD-L1 antibody. In certain embodiments, an additional therapy is provided to the subject suffering from cancer.

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1A-D. Anti-tumor immunity elicited by viral delivered IL-2. The antitumor effect of vvDD-mIL-2 in murine tumor models: anti-tumor effects of oncolytic vaccinia virus armed with secretable IL-2 on various types of cancer in syngeneic mice. (A) Experimental scheme. (B-D) Percent survival of immunocompetent mice treated with either phosphate buffered saline (PBS; dotted line), unarmed vvDD virus (black line) or mIL-2 “armed” vvDD-mIL-2 (gray line) five days after inoculation with (B) MC38-luc colon cancer cells; (C) ID8-luc ovarian cancer cells; or (D) AB12-luc mesothelioma cells. Specifically, B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells (MC38 colorectal cancer model in C57BL/6 (B6) mice) (B) or 3.5×10^6 ID8-luc (ID8 ovarian cancer model in B6 mice) (C) or BALB/c mice were intraperitoneally inoculated with 4×10^5 AB12-luc (AB12 mesothelioma model in BALB/c mice) (D), and treated with PBS, vvDD and vvDD-IL-2 5 days post tumor inoculation. The survival of tumor-bearing mice was shown by Kaplan-Meier analysis. In all of the figures, the standard symbols for *P* values are, * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; and **** $P < 0.0001$.

FIGURE 2A-B. The toxicity of vvDD-mIL-2 in a late stage murine tumor model: vvDD-mIL-2 elicits strong toxic effects when treating more advanced MC38 colon cancer model in B6 mice. (A) Experimental scheme. (B) Percent survival of mice treated with either phosphate buffered saline (PBS; dotted line), unarmed vvDD virus (black line) or mIL-2 “armed” vvDD-mIL-2 virus (gray line) nine days after inoculation with MC38-luc colon cancer cells. MC38 tumor model is normally treated on day 5. However, when treated on day 9, the expression of secreted IL-2 caused fatal effects in tumor-bearing mice.

FIGURE 3. Examples of oncolytic viruses armed with immune-stimulatory molecules for elicitation of potent adaptive antitumor immunity. The examples include, but not limited to, vvDD-mIL-2-GPI and vvDD-IL-23. (A) Diagram of insertion, in vvDD thymidine kinase (*tk*) gene, of p7.5e/l viral promoter operably linked to murine IL-2-encoding nucleic acid fused to (G4S)₃ linker and GPI anchor-encoding sequences, in virus denoted vvDD-mIL-2-GPI. This construct also contains nucleic acid encoding yellow fluorescent protein (“yfp”) operably linked to the pSe/l promoter as a detectable marker. (B) Diagram of insertion, in vvDD thymidine kinase (*tk*) gene, of p7.5e/l viral promoter operably linked to murine IL-23p19-encoding nucleic acid fused to IRES linker and murine IL-23p40 anchor-encoding sequences, in virus denoted vvDD-mIL-23p19-IRES. This construct also contains nucleic acid encoding yellow fluorescent protein (“yfp”) operably linked to the pSe/l promoter as a detectable marker.

FIGURE 4A-B. Flow cytometry data. (A) B16 melanoma cells infected with either vvD virus (left-most panel), vvDD-mIL-2 virus (center panel) or vvDD-mIL-2-GPI virus (right-most panel). (B) MC38 colon cancer cells infected with either vvD virus (left-most panel), vvDD-mIL-2 virus (center panel) or vvDD-mIL-2-GPI virus (right-most panel).

FIGURE 5A-B. The expression intensity of IL-2 on cell membrane (A) in B16 cells infected with vvDD-mIL-2 or vvDD-mIL-2-GPI; (B) in MC38-luc cells infected with vvDD-mIL-2 or vvDD-mIL-2-GPI.

FIGURE 6A-B. The oncolytic viruses expressing IL-12 display significant therapeutic effect in early colon cancer model (day 5). (A) Experimental scheme. (B) Percent survival of mice treated with either phosphate buffered saline (PBS; dotted line), vvDD virus (black line), vvDD-mIL-2 virus (thin black line that stays at 100 percent) or IL-2 “anchored” vvDD-mIL-2-GPI (gray line) 5 days after inoculation with MC38-luc colon cancer cells (experimental scheme in upper part of the figure).

FIGURE 7A-B. (A) Experimental scheme. (B) Treatment mortality of MC38-luc tumor-bearing mice treated with either vvDD-mIL-2 (left bar) or vvDD-mIL-2-GPI (right bar) nine days after inoculation with MC38-luc colon cancer cells.

FIGURE 8A-C. Adoptive transfer of tumor infiltrated T cells - induced by oncolytic virus (“OV-induced T cells”) (isolated from vvDD-IL-2 treated MC38 tumor-bearing mice and *ex vivo* expanded) led to significant therapeutic effects in syngeneic C57BL/6 mice bearing peritoneal MC38 tumor. (A) Timeline of experimental setup. (B) The survival of tumor-bearing mouse was monitored by Kaplan-Meier analysis. (C) Live

imaging of the mice with MC38-luc tumors at day 21 post treatment and (D) at day 28 post treatment.

FIGURE 9. Schematic diagram of viral IL-2 variants. vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG and vvDD-IL-2-FPTM were generated by homologous

5 recombination of murine *IL-2* variants into the *tk* locus of vaccinia viral genome, carrying secreted IL-2, IL-2-flexible linker (G₄S)₃-GPI anchor sequence amplified from human CD16b, IL-2- rigid linker A(EA₃K)₄AAA-GPI anchor sequence amplified from human CD16b, IL-2-flexible linker (G₄S)₃-murine PD-L1 transmembrane domain, respectively.

FIGURE 10A-B. Viral replication and cytotoxicity *in vitro*. Tumor cells MC38-luc, B16 and AB12-luc were mock-infected or infected with indicated viruses. The
10 production of virus progeny from infected cancer cells at 48 h post infection was determined by plaque assay (A), or the viability of viral infected cells was determinate by MTS assay (B).

FIGURE 11A-C. The expression and antitumor effect of viral delivered IL-2. (A)
15 Tumor cell MC38-luc (3×10^5 cells), B16 (2×10^5 cells) or AB12-luc (3×10^5 cells) were mock-infected or infected with vvDD, vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG and vvDD-IL-2-FPTM at MOI of 1. The culture supernatants were harvested for measuring secreted IL-2 by ELISA or membrane-associated IL-2 by flow cytometry 24 hours post infection. (B) B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and
20 treated with PBS, vvDD, vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG and vvDD-IL-2-FPTM at 2×10^8 PFU/mouse 5 days post tumor inoculation. (C) B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated with PBS, vvDD, vvDD-IL-2, vvDD-IL-2-FG and vvDD-IL-2-RG at 2×10^8 PFU/mouse 9 days post tumor inoculation. The survival of tumor-bearing mice was shown by Kaplan-Meier analysis.
25 The standard symbols for *P* values are, * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; and **** $P < 0.0001$.

FIGURE 12A-B. Viral delivered IL-2 expression in tumor cells. Tumor cells MC38-luc, B16, or AB12-luc were mock-infected or infected with vvDD, vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG and vvDD-IL-2-FPTM at MOI of 1. The infected cells
30 were harvested 24 h post infection for RNA purification. Purified total RNAs were subject to RT-qPCR for quantitative detection of A34R mRNA (viral gene) (A) or IL-2 (B).

FIGURE 13. Systemic antitumor immunity elicited by viral IL-2 variants.

MC38-luc-tumor-bearing B6 mice treated with indicated vaccinia viruses, which survived more than 60 days, were subcutaneously rechallenged with 5×10^5 MC38-luc cells per mouse. And naïve B6 mice received same dose tumor challenge as a control. The growth curves of primary tumors were shown.

Figure 14A-H. The more immunosuppressive microenvironment in 9-day-tumor-bearing mice. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and tumor tissues were harvested 5 days or 9 days post tumor inoculation. Primary tumors were photoed (A), weighed (B), and lysed to make single cells and stained to determine the presence of $CD4^+Foxp3^+$ (C), G-MDSC ($CD11b^+Ly6G^+Ly6C^{lo}$) (D), $CD4^+PD-1^+$ (E), $CD8^+PD-1^+$ (F), $CD3^+NK1.1^+$ (G), and $PD-L1^+$ (H) cells in the tumor microenvironment.

FIGURE 15A-C. The elevated expression of immunosuppressive factors and edema in 9-day-tumor-bearing mice. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and mouse tissues were harvested 5 days or 9 days post tumor inoculation. (A) Primary tumors were applied to extract RNA for RT-qPCR to determine the expression of immunosuppressive factors. Livers and kidneys were harvested, weighed and dried to measure water content to determine liver edema (B) and lung edema (C).

FIGURE 16A-E. Toxicity profile of viral delivered IL-2. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated with PBS, vvDD, vvDD-IL-2, vvDD-IL-2-FG and vvDD-IL-2-RG at 2×10^8 PFU/mouse 9 days post tumor inoculation. The mice died earlier than PBS-treated mice, generally within 7 days post viral treatment, were counted as IL-2-induced death. The treatment related mortality was shown in (A). The treated mice were sacrificed 4 to 5 days post treatment for collecting blood to measure IL-2 (B) and $TNF-\alpha$ (C) in sera, and for monitoring lung edema (D) and liver edema (E). The standard symbols for *P* values are, * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; and **** $P < 0.0001$.

FIGURE 17A-D. The toxicity profile of vaccinia virus delivered IL-2 in early-stage-tumor-model. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated with vvDD, vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG, or PBS 5 days post tumor inoculation. The treated mice were sacrificed 8 days post treatment to harvest tissues to measure water content to determine edema in lung (A), liver (B) and kidney (C), or to harvest blood to measure IL-2 (D) in sera.

FIGURE 18A-N. Immune status change in tumor microenvironment post virus treatments. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated with PBS, vvDD, vvDD-IL-2-FG and vvDD-IL-2-RG at 2×10^8 PFU/mouse 9 days post tumor inoculation. Tumor-bearing mice were sacrificed 5 days post treatment and primary tumors were collected and analyzed by flow cytometry to determine $CD4^+Foxp3^-$ and $CD8^+IFN-\gamma^+$ T cells (A, B), memory-phenotype T cells ($CD8^+CD44^{hi}$) (C), Regulatory T cells ($CD4^+Foxp3^+$) (D), CD8/Treg (E), or by RT-qPCR to determine IFN- γ , Granzyme B, Perforin, TGF- β , CD105, VEGF and IL-10 (F-I). In a separate experiment, B6 mice were inoculated with 5×10^5 MC38-luc cells i.p. and treated with vvDD-IL-2-RG or PBS 9 days post tumor inoculation. α -CD8 Ab (250 μ g/injection), α -NK1.1 Ab (300 μ g/injection), α -CD4 Ab (150 μ g/injection), or α -IFN- γ Ab (200 μ g/injection) were intraperitoneally injected into mice to deplete $CD8^+$ T cells, NK1.1 $^+$ cells, $CD4^+$ T cells or neutralize circulating IFN- γ as scheduled (M), and the overall survival was shown by Kaplan-Meier analysis (N).

FIGURE 19A-D. The memory-phenotype $CD8^+$ T cells and NK cells in 9-day-tumor-bearing mice. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated as described in Fig. 18. Primary tumors and spleens were harvested 5 days post viral treatment and applied to make single cells and stained to determine $CD8^+CD44^{hi}$ in spleen (A), $CD3^+NK1.1^+$ in tumor (B) and spleen (C), $CD8^+$ T cells in tumor (D).

FIGURE 20. The elevated NKP46 expression in 9-day-tumor-bearing mice post viral treatment. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated as described in Fig. 18. Primary tumors were harvested and applied to extract RNA for RT-qPCR to determine the expression of NKP46.

FIGURE 21A-B. The antitumor efficacy of vvDD combined with PD-L1 blockade. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated as scheduled (A), and the overall survival was shown by Kaplan-Meier analysis (B).

FIGURE 22A-E. Viral treatment apt to the combination with immune checkpoint therapy. B6 mice were inoculated with 5×10^5 MC38-luc cells and treated as described in Figure 18. Tumor-bearing mice were sacrificed 5 days post treatment and primary tumors were collected and analyzed by RT-qPCR to determine the expression of PD-1, PD-L1, and CTLA-4 (A-C). In a separate experiment, B6 mice were intraperitoneally inoculated

with 5×10^5 MC38-luc cells and treated with vvDD-IL-2-RG or PBS 9 days post tumor inoculation. α -PD-1 Ab (200 μ g/injection), α -PD-L1 Ab (200 μ g/injection), or α -CTLA-4 Ab (100 μ g/injection) were intraperitoneally injected into mice as scheduled (D), and the overall survival was shown by Kaplan-Meier analysis (E).

5 FIGURE 23A-C. The elevated exhausted T cells and PD-L1⁺ cells in 9-day-tumor-bearing mice post viral treatment. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated as described in Fig. 18. Primary tumors were harvested and applied to make single cells and stained to determine CD4⁺PD-1⁺ (A) and CD8⁺PD-1⁺ (B) T cells, and PD-L1⁺ cells (C).

10 FIGURE 24A-B. The antitumor efficacy of vvDD-IL-2-FG combined immune checkpoint therapy. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and treated with vvDD-IL-2-FG or PBS 9 days post tumor inoculation. α -PD-1 Ab (200 μ g/injection), α -PD-L1 Ab (200 μ g/injection), or α -CTLA-4 Ab (100 μ g/injection) were intraperitoneally injected into mice as scheduled (A), and the overall survival was
15 shown by Kaplan-Meier analysis (B).

FIGURE 25A-C. CD8⁺ T cell response in the tumor microenvironment (TME) of MC38 s.c. tumors 10 days post virus treatment. (A) Experimental setup: B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ vvDD, vvDD-IL-2, vvDD-IL-15, vvDD-CXC11, vvDD-CCL5 (1×10^8 pfu per tumor) or
20 PBS was intratumorally injected (n=4-5 per group). 10 days later tumors have been collected and proceed to single cell suspension followed by magnetic separation (CD8 negative selection) for IFN- γ ELISPOT. (B) CD8⁺ T cells have been analyzed for IFN- γ production by ELISPOT. CD8⁺ T cells (2×10^4 per well) were either left unstimulated (control) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) for 24 h.
25 Results are shown as individual data points (number of spots in each well) and bars (means $\pm$ standard deviation) of CD8⁺ T cells from each mouse evaluated in triplicates. To determine MC38 reactive responses the average value of spots from control wells were subtracted from the number of spots in MC38 challenged wells. Data were presented as individuals and means. Student's t-test was used to analyze the statistical
30 significance (*p<0.05). (C) The virus induced CD8⁺ T cells in the TME are tumor specific. B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ vvDD, vvDD-IL-2 (1×10^8 pfu per tumor) or PBS was intratumorally injected (n=7 per group, Data are presented as summary of two independent experiments). 10 days later tumors have been collected and proceed to

single cell suspension followed by magnetic separation (CD8 negative selection). CD8⁺ T cells have been analyzed for IFN- γ production by ELISPOT. CD8⁺ T cells (2×10^4 per well) were either left unstimulated (medium control) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse for 24 h. Results are shown as individual data points (number of spots in each well) and bars (means $\pm$ standard deviation) of CD8⁺ T cells from each mouse evaluated in duplicate. Student's t-test was used to analyze the statistical significance (* $p < 0.05$).

FIGURE 26A-B. CD8⁺ T cell response in the TME of MC38 s.c. tumors induced by vvDD-IL-2 is superior to IL-2 treatment. B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ IL-2 (1×10^6 IU per tumor), vvDD, vvDD-IL-2 (1×10^8 pfu per tumor) or PBS was intratumorally injected (n=4-5 per group). 10 days later tumors have been collected and proceed to single cell suspension followed by magnetic separation (CD8 negative selection). (A) To determine the local immune response CD8⁺ T cells have been analyzed for IFN- γ production by ELISPOT. CD8⁺ T cells (2×10^4 per well) were either left unstimulated (control) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) for 24 h. Results are shown as individual data points (number of spots in each well) and bars (means $\pm$ standard deviation) of CD8⁺ T cells from each mouse evaluated in triplicates. To determine tumor reactive responses the average value of spots from control wells were subtracted from the number of spots in MC38 challenged wells. Student's t-test was used to analyze the statistical significance (* $p < 0.05$). (B) For analysis of the systemic immune response additionally the spleen from each mouse has been harvested and proceeded to single cell suspension. Splenocytes have been analyzed for IFN- γ production by ELISPOT. Splenocytes (1×10^5 per well) were either left unstimulated (control) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) for 24 h. Results are shown as individual data points (number of spots in each well) and bars (means $\pm$ standard deviation) of splenocytes from each mouse evaluated in triplicates. To determine tumor reactive responses the average value of spots from control wells were subtracted from the number of spots in MC38 challenged wells. Student's t-test was used to analyze the statistical significance (* $p < 0.05$).

FIGURE 27A-B. vvDD-IL-2 and vvDD treatment increase the number of tumor infiltrating T cells. (A) B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ PBS or vvDD, vvDD-IL-2 (1×10^8 pfu per tumor) was intratumorally injected (n=5 per group). 10 days later tumors have been collected,

fixed and stained for DAPI, CD3, CD4, CD8. Representative immunofluorescence image of one sample from each group. (B) Summary of the percentage of CD3⁺ T cells and CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells per area.

FIGURE 28. vvDD-IL-2 and vvDD treatment increases the number of T cells in the tumor. B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ vvDD, vvDD-IL-2 (1×10^8 pfu per tumor) or PBS was intratumorally injected (n=8 per group). 10 days later tumors have been collected and proceed to single cell suspension followed by magnetic separation (CD90.2 beads). T cells from each individual mouse have been counted and calculated per gram tumor. Student's t-test was used to analyze the statistical significance (*p<0.05).

FIGURE 29A-C. Tumor Infiltrated T Cells - Induced by Oncolytic Virus ("OV-induced T cells") can be cultured ex vivo and keep their tumor specificity. (A) Experimental setup: B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ vvDD, vvDD-IL-2 (1×10^8 pfu per tumor) or PBS was intratumorally injected (n=4 per group, Data are presented as summary of 2 independent experiments). 10 days later tumors have been collected and proceed to single cell suspension followed by magnetic separation (CD90.2 beads). T cells from each individual mouse have been cultured in 24-well plates (1×10^6 per well) in RPMI complete media in the presence of IL-2 (30 IU/ml) and IL-7 (5ng/ml). (B) To determine the tumor specificity of the T cells under culture conditions, T cells from each individual mouse have been tested after 4 days for IFN- γ production by ELISPOT. T cells (2×10^4 per well) were either left unstimulated (medium) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse in duplicate for 24 h. Results are shown as individual data points (number of spots in each well) and bars (means $\pm$ standard deviation) of T cells from each mouse evaluated in duplicate. Student's t-test was used to analyze the statistical significance (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). (C) Besides IFN- γ ELISPOT the T cells have been tested for 4-1BB upregulation by flow cytometry. T cells (2×10^4 per well) were either left unstimulated (medium control) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse in duplicate. After 24h the cells have been stained for flow cytometry analysis against CD3, CD4, CD8, 4-1BB. Results are shown as individual data points (percentage of CD8⁺4-1BB⁺ T cells and

CD4⁺4-1BB⁺ T cells) and bars (means $\pm$ standard deviation) of T cells from each mouse evaluated in duplicate. Student's t-test was used to analyze the statistical significance (* p <0.05; ** p <0.01; *** p <0.001; **** p <0.0001).

FIGURE 30. Representative flow cytometry plot of CD8⁺4-1BB⁺ and CD4⁺4-1BB⁺ T cells of one sample from each group.

FIGURE 31A-C. *In vitro* analysis of the vvDD-IL-2 induced T cells versus naïve T cells prior to adoptive T cell transfer. Prior to ACT the cultured T cells have been tested for tumor reactivity *in vitro* using IFN- γ ELISPOT and co-culture assay for flow cytometry staining of 4-1BB expression and IFN- γ ELISA. For ELISPOT and the co-culture assay T cells (2×10^4 per well) were either left unstimulated (medium) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse in duplicate for 24 h. (A) ELISPOT Results are shown as individual data points (number of spots in each well) and bars (means $\pm$ standard deviation) of T cells from each mouse evaluated in in duplicate. (B and C) Besides IFN- γ ELISPOT the T cells have been tested for 4-1BB Expression by flow cytometry. The cells (2×10^4 per well) were either left unstimulated (medium control) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse in duplicate. After 24 h the cells have been stained for FLOW analysis against CD3, CD4, CD8, 4-1BB. Results are shown as individual data points (percentage of CD8⁺4-1BB⁺ T cells and CD4⁺4-1BB⁺ T cells) and bars (means $\pm$ standard deviation) of T cells from each mouse evaluated in duplicate. Student's t-test was used to analyze the statistical significance (* p <0.05; ** p <0.01; *** p <0.001; **** p <0.0001).

FIGURE 32. Representative flow cytometry plot of CD8⁺4-1BB⁺ and CD4⁺4-1BB⁺ T cells of one sample from each group.

FIGURE 33A-C. Adoptive T cell transfer of vvDD-IL-2 induced T cells into MC38 i.p. tumor bearing mouse. (A) Experimental setup: To generate virus induced T cells for adoptive T cell transfer B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells (n=12). When the tumor area reached $5 \times 5 \text{ mm}^2$ vvDD-IL-2 (1×10^8 pfu per tumor) was intratumorally injected. 10 days later tumors have been collected (2 samples have been pooled together, n=6) and proceed to single cell suspension followed by magnetic separation (CD90.2 beads). T cells have been expanded in 24-well plates (1×10^6 per

well) in RPMI complete media in the presence of IL-2 (30 IU/ml) and IL-7 (5ng/ml). As control T cells, spleens from non-tumor bearing untreated mouse (n=4) have been harvested and proceed to single cell suspension followed by magnetic separation (CD90.2 beads). The naïve T cells have been cultured under the same conditions as the virus induced T cells. T cells have been harvested for adoptive transfer (5×10^6 T cells per mouse) 4 days later. The ACT treatment mouse have been intraperitoneally inoculated with 5×10^5 MC38-luc cancer cells 7 days prior to treatment and divided into required groups according to tumor growth condition based on live animal IVIS imaging 7 days post tumor cell injection (n=7). Prior to T cell transfer treated mouse received 5 Gy of sublethal irradiation to mimic lymphodepletion similar to clinical protocols. Grouped mouse were intraperitoneally injected with vvDD-IL-2 induced T cells, naïve T cells or PBS. All treated mouse received exogenous cytokine support of IL-2 (100.000 IU/mouse i.p. for 3 days every 12 h). (B) The survival of tumor-bearing mouse was monitored by Kaplan-Meier analysis. (C) The tumor growth has been monitored by live animal imaging.

FIGURE 34. Imaging Day 17 post ACT.

5. DETAILED DESCRIPTION OF THE INVENTION

For clarity and not by way of limitation, the detailed description of the presently disclosed subject matter is divided into the following subsections:

- (i) Oncolytic viruses;
- (ii) Immunomodulator molecules;
- (iii) Armed oncolytic viruses;
 - a. Secreted immunomodulator molecules;
 - b. Membrane bound immunomodulator molecules;
 - i. Anchoring peptides;
 - ii. Linkers;
 - iii. Non-limiting embodiments;
- (iv) Oncolytic virus administration;
- (v) Methods of manufacture;
 - a. Isolation and preparation of tumor infiltrated T cells - induced by oncolytic virus ("OV-induced T cells");
- (vi) Methods of treatment;
 - a. Adoptive T-cell therapy;

- b. Treatment with armed oncolytic viruses;
- (vii) Pharmaceutical compositions; and
- (viii) Kits.

5

5.1. ONCOLYTIC VIRUSES

The presently disclosed subject matter can be applied to any oncolytic virus known in the art. An “oncolytic virus” is a virus that exhibits increased replication in, and lysis of, cancer cells relative to comparable non-cancer cells; *see*, for example, Bartlett DL et al., 2013, Molecular Cancer 12:103-120; Kaufman HL et al., 2015, Nature Reviews Drug Discovery 14:642–662 and Chiocca EA and Rabkin SD, 2014, Cancer Immunol Res; 2; 295–300. In certain embodiments, the oncolytic virus exhibits selective replication in cancer cells and less or essentially no replication in non-cancer cells. In certain embodiments, less replication means that replication in cancer cells versus comparable non-cancer cells is at least about 30 percent greater, or at least about 50 percent greater, or at least about 80 percent greater.

The term “about” or “approximately,” as used herein, can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, *e.g.*, the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the given value. Where particular values are described in the application and claims, unless otherwise stated the term “about” can mean an acceptable error range for the particular value, such as $\pm 10\%$ of the value modified by the term “about.”

Non-limiting examples of oncolytic viruses include types of (i) adenovirus (“Ad”), for example hTERT-Ad; (ii) herpes simplex virus (“HSV”), for example G207, HSV-1716, T-VEC, and HSV-2 Δ PK mutant; (iii) poxvirus, for example vaccinia virus, for example vSP and vvDD (*tk*-/*vgf*-) (and *see* below); (iv) arbovirus; (v) paramyxovirus, for example, measles virus, mumps and Newcastle disease virus; (vi) rhabdovirus, for example, vesicular stomatitis virus; (vii) picornavirus, for example Cocksackie virus, Seneca Valley Virus, and polio virus; (viii) reovirus; (ix) parvovirus; and (x) recombinant/engineered versions of any one of the above.

In certain embodiments, the oncolytic virus is an oncolytic virus that has been approved by the Food and Drug Administration (FDA) or is undergoing clinical trials. For example, but not by way of limitation, the oncolytic virus can be Talimogene

laherparepvec (Imlygic™; Amgen, Inc.), also referred to as T-VEC. In certain embodiments, the oncolytic virus can be pelareorep (Reolysin®; Oncolytics Biotech, Inc.). In certain embodiments, the oncolytic virus can be DNX-2401 (DNATRIX Therapeutics). In certain embodiments, the oncolytic virus can be H101 (Oncorine®; Shanghai Sunway Biotech Co., Ltd.). In certain embodiments, the oncolytic virus can be pexastimogene devacirepvec (JX- 594; SillaJen Inc.). In certain embodiments, the oncolytic virus can be CG0070 (Cold Genesys, Inc.). In certain embodiments, the oncolytic virus can be G47Δ (Daiichi-Sankyo Company, Limited).

In certain embodiments, the oncolytic virus is a vaccinia virus. In certain non-limiting embodiments, the oncolytic virus is an engineered (also referred to as “recombinant”) vaccinia virus. In certain non-limiting embodiments, the virus is a recombinant vaccinia virus based on the Western Reserve (“WR”) strain of vaccinia, for example, the WR strain commercially available from the American Type Culture Collection as ATCC No. VR1354. Other vaccinia virus strains suitable for engineering include, but are not limited, to the Wyeth strain (ATCC VR-1536), the Lederle-Chorioallantoic strain (ATCC VR-325), and the CL strain (ATCC VR-117).

In certain non-limiting embodiments, the oncolytic virus is an engineered vvDD vaccinia viral construct comprising, for example, a modified version of a virus described in United States Patent No. 7,208,313, United States Patent No. 8,506,947, and United States Patent Application Publications Nos. 2003/0031681 and 2007/0154458, McCart et al., 2001, Cancer Research 61:8751-8757 and/or Thorne S et al., 2007, J. Clin. Invest. 117:3350-3358, all of which are incorporated by reference herein in their entries. For example, but not by way of limitation, the vaccinia virus can have deletions of the thymidine kinase (*tk*) and/or vaccinia growth factor (*vgf*) genes.

In certain non-limiting embodiments, a vaccinia virus has an inactivating mutation in one or more gene where the product of said gene or genes functions in viral replication. For example, but not by way of limitation, one or more of the following genes can bear an inactivating mutation: the gene encoding the ribonucleotide reductase-large subunit, the gene encoding the ribonucleotide reductase-small subunit, the gene encoding thymidylate kinase, the gene encoding DNA ligase, the gene encoding dUTPase, the *tk* gene, and the vaccinia virus growth factor (*vgf*) gene. In certain embodiments, an inactivating mutation is a mutation that either reduces or eliminates activity of the gene product. In certain embodiments, gene activation can be achieved by mutagenesis, *e.g.*, site-directed mutagenesis or PCR-mediated mutagenesis.

Alternatively or additionally, in certain embodiments, a nucleic acid can be inserted into one or more of the foregoing genes to achieve inactivation. In certain non-limiting embodiments, a nucleic acid encoding a protein can be inserted into one or more of the foregoing genes to achieve inactivation and to further achieve expression of the nucleic acid. In certain embodiments, a nucleic acid encoding an immunomodulator molecule can be inserted within one of the foregoing genes to achieve inactivation. In certain embodiments, a nucleic acid encoding an immunomodulator molecule linked to an anchoring peptide (*e.g.*, an ANCHIM protein) can be inserted within one of the foregoing genes to achieve inactivation and, optionally, the ANCHIM protein can be expressed.

In certain non-limiting embodiments, the oncolytic virus is a vaccinia virus having an inactivating mutation (a mutation that either reduces or eliminates activity of the gene product) in the *tk* gene. For example, but not limited to, the inactivation of the thymidine kinase gene can be generated by the insertion of a cytosine deaminase (*fcyl*) gene within the thymidine kinase gene locus of the vaccinia viral genome, resulting in the expression of the *fcyl* gene rather than the *tk* gene. In another non-limiting embodiment, a nucleic acid encoding a detectable protein, for example a fluorescent protein, for example yellow fluorescent protein (“yfp”), can be inserted into the *tk* gene, thereby inactivating it. In certain embodiments, a nucleic acid encoding an immunomodulator can be inserted into the *tk* gene. In certain embodiments, a nucleic acid encoding an ANCHIM protein can be inserted into the *tk* gene.

In additional or alternative embodiments, the recombinant vaccinia virus can have an inactivating mutation in the vaccinia growth factor gene. For example, but not by way of limitation, an insertion of a *lacZ* gene within the *vgf* gene locus, resulting in the expression of the *lacZ* gene rather than *vgf*. In certain embodiments, a nucleic acid encoding an immunomodulator can be inserted into the *vgf* gene. For example, but not by way of limitation, a nucleic acid encoding an ANCHIM protein can be inserted into the *vgf* gene.

5.2. IMMUNOMODULATOR MOLECULES

Any immunomodulator molecule known in the art can be utilized according to the presently disclosed subject matter. Certain cytokines have immunomodulatory activity and would be considered immunomodulator molecules (or, simply, “immunomodulators”) herein.

In certain embodiments, an immunomodulator molecule can comprise a cytokine. In certain embodiments, an immunomodulator molecule can comprise a chemokine. Non-limiting examples of immunomodulator molecules which can be used according to the presently disclosed subject matter include an interleukin ("IL"), for example IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24 or IL-27, C-X-C motif chemokine 11 (CXCL11), Chemokine (C-C motif) ligand 5 (CCL5), an interferon ("IFN"), for example, IFN-alpha, IFN-alpha2, IFN-beta, or IFN-gamma; or a tumor necrosis factor ("TNF"), for example TNF-alpha or TNF-beta; and granulocyte macrophage colony-stimulating factor (GM-CSF).

The immunomodulator molecule can be a human or non-human immunomodulator molecule. Nucleic acid sequences encoding such immunomodulator molecules, and the encoded protein sequences, are well known in the art. Examples of non-human species include non-human primates, rodents, rabbits, dogs, cats, horses, pigs, sheep, cows, etc.

In certain non-limiting embodiments, the immunomodulator molecule for use in the presently disclosed subject matter is IL-2. In certain embodiments, human IL-2 comprises at least an immune-activating portion of the sequence APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO:13; GenBank Acc. No. CAA25742.1, residues 21-153), or conservative substitutions thereof, *e.g.*, said sequence having one or two amino acid variations.

In certain non-limiting embodiments, the immunomodulator molecule for use in the presently disclosed subject matter is TNF-alpha. In certain non-limiting embodiments, the human TNF-alpha comprises at least an immune-activating portion of the sequence MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLCLLHFGVI GPQREEFPRDLSLISPLAQAVRSSSRTPSDKPVAVHVVANPQAEGQLQWLNRRANA LLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTK VNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAE SGQVYFGIHAL (SEQ ID NO:15; NCBI Ref. Sequence No. NM_000594.3) or conservative substitutions thereof, *e.g.*, said sequence having one or two amino acid variations.

In certain non-limiting embodiments, the immunomodulator molecule for use in the presently disclosed subject matter is IL-23, which consists of the two subunits, IL-23A and IL-12B. In certain non-limiting embodiments, the human IL-23A protein comprises at least an immune-activating portion of the sequence

- 5 MLGSRVMLLLLLPWTAAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVG
HMDLREEGDEETTNDVPHIQCGDGC DPQGLRDNSQFCLQRIHQGLIFYEKL LGSD
IFTGEPSLLPDSPVGQLHASLLGLS QLLQPEGHHWETQQIPSLSPSQPWQRLLLR F
KILRSLQAFVAVAARVFAHGAATLSP (SEQ ID NO:18; GenBank Acc. No. XXX,
residues 1-189 or amino acid residues 28-184 of SEQ ID NO:18), or said sequence
10 having one amino acid variation.

In certain non-limiting embodiments, the presently disclosed subject matter can also be applied using a non-immunomodulator cytokine where said cytokine is desirably localized to the cancer cell environment, for example where said cytokine exhibits toxic effects when systemically administered.

As used herein, the terms “conservative amino acid substitutions” and “conservative modifications” refer to amino acid modifications that do not significantly affect or alter the function and/or activity of the presently disclosed proteins comprising the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the proteins of this disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Amino acids can be classified into groups according to their physicochemical properties such as charge and polarity.

Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid within the same group. For example, amino acids can be classified by charge: positively-charged amino acids include lysine, arginine, histidine, negatively-charged amino acids include aspartic acid, glutamic acid, neutral charge amino acids include alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In addition, amino acids can be classified by polarity: polar amino acids include arginine (basic polar), asparagine, aspartic acid (acidic polar), glutamic acid (acidic polar), glutamine, histidine (basic polar), lysine (basic polar), serine, threonine, and tyrosine; non-polar amino acids include alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, and valine. In certain embodiments, no more than one, no more than two, no more than three, no

more than four, no more than five residues within a specified sequence are altered. Exemplary conservative amino acid substitutions are shown in Table 1 below.

Table 1

Original Residue	Exemplary Conservative Amino Acid Substitutions
Ala (A)	Val; Leu; Ile
Arg (R)	Lys; Gln; Asn
Asn (N)	Gln; His; Asp, Lys; Arg
Asp (D)	Glu; Asn
Cys (C)	Ser; Ala
Gln (Q)	Asn; Glu
Glu (E)	Asp; Gln
Gly (G)	Ala
His (H)	Asn; Gln; Lys; Arg
Ile (I)	Leu; Val; Met; Ala; Phe
Leu (L)	Ile; Val; Met; Ala; Phe
Lys (K)	Arg; Gln; Asn
Met (M)	Leu; Phe; Ile
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr
Pro (P)	Ala
Ser (S)	Thr
Thr (T)	Val; Ser
Trp (W)	Tyr; Phe
Tyr (Y)	Trp; Phe; Thr; Ser
Val (V)	Ile; Leu; Met; Phe; Ala

5.3. ARMED ONCOLYTIC VIRUSES

The presently disclosed subject matter provides for an oncolytic virus that comprises a nucleic acid that encodes an immunomodulator molecule as set forth above. In certain embodiments, the immunomodulator molecule encoding by the nucleic acid can be secreted, *e.g.*, secreted from the cell infected by the oncolytic virus that comprises the nucleic acid. In certain embodiments, the immunomodulator molecule can be linked to an anchoring peptide to become membrane-associated.

5.3.1. Secreted Immunomodulator Molecules

The presently disclosed subject matter provides for an oncolytic virus that comprises a nucleic acid that encodes an immunomodulator molecule that is to be secreted, *e.g.*, secreted from the cell infected by the oncolytic virus that comprises the nucleic acid. Suitable oncolytic viruses and immunomodulator molecules are discussed in the sections above. In certain embodiments, the immunomodulator molecule can be of the same species as the subject intended to be treated (for example a human immunomodulator molecule to treat a human subject) or can be of a different species (for example a mouse immunomodulator molecule to treat a human subject).

In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic virus, comprising, in its genome, a nucleic acid, encoding an immunomodulator molecule. In certain embodiments, the oncolytic virus is a herpes simplex virus, a vaccinia virus, an adenovirus or a vesicular stomatitis virus.

In certain embodiments, the immunomodulator molecule can be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, CXCL11, CCL5, an IFN, IFN-alpha, IFN-alpha2, IFN-beta, IFN-gamma, a TNF, TNF-alpha, TNF-beta, GM-CSF or a combination thereof. In certain embodiments, the immunomodulator molecule is IL-2. In certain embodiments, the immunomodulator molecule is IL-23. In certain embodiments, the immunomodulator molecule is TNF-alpha.

In certain embodiments, the nucleic acid encoding the immunomodulator molecule can be placed under the control of a promoter that is active or activatable in an oncolytic virus infected cell, for example, a promoter of the oncolytic virus. The encoding nucleic acid can be DNA, RNA or cDNA to conform to the nucleic acid of the viral genome into which it is inserted.

In certain embodiments, the oncolytic virus is a herpes simplex virus. In certain embodiments, the herpes virus comprises, in its genome, a nucleic acid that encodes an

immunomodulator molecule, as described above. In certain embodiments, the nucleic acid encoding the immunomodulator molecule can be placed under the control of a promoter that is active or activatable in a herpes simplex virus infected cell, for example, a promoter of the herpes simplex virus. The encoding nucleic acid can be DNA to conform to the nucleic acid of the genome of the herpes simplex virus. In certain embodiments, an oncolytic virus of the present disclosure can be a herpes simplex virus that comprises a nucleic acid that encodes IL-2. In certain embodiments, an oncolytic virus of the present disclosure can be a herpes simplex virus that comprises a nucleic acid that encodes IL-23. In certain embodiments, an oncolytic virus of the present disclosure can be a herpes simplex virus that comprises a nucleic acid that encodes TNF-alpha.

In certain embodiments, the oncolytic virus is a vaccinia virus. In certain embodiments, the nucleic acid encoding the immunomodulator molecule is operably linked to a promoter active or activatable in a vaccinia virus-infected cell, for example, a vaccinia virus promoter. In certain non-limiting embodiments, the nucleic acid encoding the immunomodulator molecule can be operably linked to a vaccinia promoter, for example the p7.5 e/l promoter, or the pSe/l promoter to generate a promoter/immunomodulator molecule-encoding construct. In certain non-limiting embodiments, the promoter/immunomodulator-encoding construct can be inserted into the *tk* gene. In certain other non-limiting embodiments, the promoter/immunomodulator-encoding construct can be inserted into the *vgf* gene. In certain embodiments, an oncolytic virus of the present disclosure can be a vaccinia virus that comprises a nucleic acid that encodes IL-2. In certain embodiments, an oncolytic virus of the present disclosure can be a vaccinia virus that comprises a nucleic acid that encodes IL-23. In certain embodiments, an oncolytic virus of the present disclosure can be a vaccinia virus that comprises a nucleic acid that encodes TNF-alpha.

In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic acid, encoding IL-2. In a specific, non-limiting embodiment, the nucleic acid can encode human IL-2 (e.g., comprising at least a portion of the amino acid sequence of SEQ ID NO:13 or conservative substitutions thereof). In certain embodiments, the nucleic acid encoding IL-2 is operably linked to a promoter active or activatable in a vaccinia virus-infected cell, for example, a vaccinia virus promoter. For example, but not by way of limitation, the nucleic acid encoding IL-2 can be operably linked to a vaccinia promoter, for example the p7.5 e/l promoter, or the pSe/l promoter to

generate a promoter/IL-2-encoding construct. In certain non-limiting embodiments, the promoter/IL-2-encoding construct can be inserted into the *tk* gene. In certain other non-limiting embodiments, the promoter/IL-2-encoding construct can be inserted into the *vgf* gene.

5 In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic acid, encoding TNF-alpha. In a specific, non-limiting embodiment, the nucleic acid can encode human TNF-alpha (*e.g.*, comprising the amino acid sequence of SEQ ID NO:15 or conservative substitutions thereof). In certain
10 embodiments, the nucleic acid encoding TNF-alpha is operably linked to a promoter active or activatable in a vaccinia virus-infected cell, for example a vaccinia virus promoter. For example, but not by way of limitation, the nucleic acid encoding TNF-alpha can be operably linked to a vaccinia promoter, for example the p7.5 e/l promoter, or the pSe/l promoter to generate a promoter/TNF-alpha-encoding construct. In certain non-
15 limiting embodiments, the promoter/TNF-alpha-encoding construct can be inserted into the *tk* gene. In certain other non-limiting embodiments, the promoter/IL-2-encoding construct can be inserted into the *vgf* gene.

In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which
20 is a deoxyribose nucleic acid, encoding the subunits of IL-23, *e.g.*, IL-23p19 and IL-23p40. In certain embodiments, the nucleic acid encoding IL-23p19 and IL-23p40 is operably linked to a promoter active or activatable in a vaccinia virus-infected cell, for example, a vaccinia virus promoter. In certain non-limiting embodiments, the oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic
25 acid, that encodes a human homologue of IL-23p19, *e.g.*, IL-23A, and a human homologue of IL-23p40, *e.g.*, IL-12B, to generate IL-23. In a specific, non-limiting embodiment, the nucleic acid can encode IL-23p19 or a human homologue thereof, for example IL-23A, and/or IL-23p40 or a human homologue thereof, for example IL-12B, and can further be operably linked to a vaccinia promoter, for example the p7.5 e/l
30 promoter, or the pSe/l promoter to generate a promoter/IL-23p19/IL-23p40-encoding construct or a promoter/IL-23A/IL-12B-encoding construct. In certain non-limiting embodiments, the promoter/IL-23p19/IL-23p40-encoding construct or a promoter/IL-23A/IL-12B-encoding construct can be inserted into the *tk* gene. In certain other non-

limiting embodiments, the promoter/IL-23p19/IL-23p40-encoding construct or a promoter/IL-23A/IL-12B-encoding construct can be inserted into the *vgf* gene.

5.3.2. Membrane Bound Immunomodulator Molecules

The presently disclosed subject matter provides for an oncolytic virus encoding a
5 membrane-associated protein comprising an immunomodulator molecule as set forth
above linked to an anchoring peptide, where the immunomodulator molecule linked to the
anchoring peptide is referred to herein as the “ANCHIM”. In certain embodiments, the
membrane attachment domain is heterologous. In certain embodiments, the membrane
attachment domain is autologous. Suitable oncolytic viruses and immunomodulator
10 molecules are discussed in the sections above. Anchoring peptides are discussed in the
sections below.

In certain embodiments, the immunomodulator molecule can be of the same
species as the subject intended to be treated (for example a human immunomodulator
molecule to treat a human subject) or can be of a different species (for example a mouse
15 immunomodulator molecule to treat a human subject).

In certain non-limiting embodiments, the presently disclosed subject matter
provides for an oncolytic virus, comprising, in its genome, a nucleic acid, encoding a
membrane-associated protein comprising an immunomodulator molecule linked to an
anchoring peptide. In certain embodiments, the oncolytic virus is a herpes simplex virus,
20 a vaccinia virus, an adenovirus or a vesicular stomatitis virus. In certain embodiments,
the immunomodulator molecule can be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, CXCL11,
CCL5, an IFN, IFN-alpha, IFN-alpha2, IFN-beta, IFN-gamma, a TNF, TNF-alpha, TNF-
beta, GM-CSF or a combination thereof. In certain embodiments, the immunomodulator
25 molecule is IL-2. In certain embodiments, the immunomodulator molecule is IL-23. In
certain embodiments, the immunomodulator molecule is TNF-alpha.

5.3.2.1. Anchoring peptides

In certain embodiments, an anchoring peptide is any protein which, when fused to
an immunomodulator molecule, anchors the immunomodulator molecule to the host cell
30 membrane. In certain embodiments, an anchoring peptide can be used according to the
presently disclosed subject matter to modify an immunomodulator molecule to bind to the
membrane of the host cell (*e.g.*, by adding a GPI or other molecule).

In certain non-limiting embodiments, the anchoring peptide is between about 10 and about 50 amino acids, or between about 15 and about 30, or about 20 amino acids in length.

5 In certain embodiments, the anchoring peptide is a glycosylphosphatidylinositol (GPI)-anchor acceptor peptide. In certain non-limiting embodiments, the GPI anchor acceptor peptide comprises at least a portion of the C terminus of its native peptide, for example comprises at least a portion of the 100 C-terminal amino acids, or at least a portion of the 50 C-terminal amino acids, of the native peptide, or at least a portion of the 30 C-terminal amino acids.

10 In certain embodiments, the anchoring peptide can comprise sequences of various proteins as well as portions of cell membrane proteins that would serve essentially the same function. As exemplified by GPI, the anchoring function can be achieved by a modification of an underlying peptide or protein that contains non-peptide elements, including but not limited to carbohydrate, lipid, etc.

15 In certain embodiments, the anchoring peptide can comprise a glycosylphosphatidylinositol (GPI)-anchor acceptor sequence of human CD16b anchor acceptor peptide. In certain non-limiting embodiments, the anchor is a GPI anchor acceptor peptide from a protein as set forth in Ferguson et al., "Chapter 11: Glycosylphosphatidyl Anchors" in Glycobiology, 2nd Edition, Varki et al., editors, Cold Spring Harbor Press, 2009, for example but not limited to alkaline phosphatase, CD58, CD14, NCAM-120 and TAG-1, the contents of which are incorporated in their entirety by reference herein.

25 In certain non-limiting embodiments, the GPI anchor acceptor peptide comprises a signal peptide portion ("SPP"), which functions during GPI addition and is cleaved in the process. In certain embodiments, a SPP comprises three domains: (1) a first domain comprising three relatively small amino acids (for example, but not limited to, Gly (G), Ala (A), Ser (S), Asn (N), Asp (D), or Cys (C) or any combination thereof) ω , $(\omega + 1)$, and $(\omega + 2)$, where ω is attached to the GPI anchor and $(\omega + 1)$ and $(\omega + 2)$ are the first 2 residues of the cleaved peptide; (2) a relatively polar domain spacer of about 5-10 amino acid residues and (3) a hydrophobic domain of about 15-20 amino acids. In certain
30 In certain embodiments, the anchoring peptide can further comprise a sequence that targets it to the endoplasmic reticulum to facilitate addition of the GPI anchor if that is not a feature viral infection (*see* Mayor S and Riezman H, 2004, Nature Reviews Molecular Cell Biology 5, 110-120, the contents of which are incorporated in their entirety by reference herein. This

signal peptide portion, extending from the protein C terminus, can be diagrammed as: ω - ($\omega+1$) - ($\omega+2$) - polar spacer region - $\sim$ hydrophobic domain (*see* Galian C et al., 2012, J. Biol. Chem. 287(20):16399-16409). In certain non-limiting embodiments, the ω - ($\omega+1$) - ($\omega+2$) - polar spacer region can include a sequence of about ten amino acids of which at least about 2 or at least about 3 residues are G and at least about 2 or at least about 3 or at least about 4 or at least about 5 residues are S. In particular non-limiting embodiments, the sequence can be NSTGSGSSGS (SEQ ID NO:17; Galian, *supra*). In certain non-limiting embodiments, the hydrophobic domain can include between about 15 and about 20 amino acids comprising at least about 10 residues selected from the group of A, Leu (L), Val (V), Phe (F) and combinations thereof. Non-limiting examples of SPPs are provided in Table 1 or Figure 8 of Galian, *supra*, and include:

GGALQSTASLFVVSLSLLHLYS (SEQ ID NO:2; from human CD24);
 NNSCSPGGCRLFLSTIPVLWTL (SEQ ID NO:3; from human EFNA2);
 DAAHPGRSVVPALLPLLAGTLLLLLETAT (SEQ ID NO:4; from human PPB1);
 SAAPRLFPLAWTVLLLPLLLLQT (SEQ ID NO:5; from human EFNA1);
 NGSISLAVPLWLLAASLLCLLSCK (SEQ ID NO:6; from human LSAMP);
 SGAPTLSPSLLGLLLPAFGILVYLEF (SEQ ID NO:7, from human CNTN1);
 NGTSRRAGCIWLLPLLVLHLLK (SEQ ID NO:8, from rat NTRI);
 NSTGSGSSGSAAAAVAAAAVAAAAVAAAA (SEQ ID NO:9); or
 NSTGSGSSGSAAAAVVFVFVFVFVAAAA (SEQ ID NO:10).

In certain embodiments, the GPI anchor acceptor peptide sequence comprises any one of peptides having SEQ ID NO: 2-10 bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions.

In a particular non-limiting embodiment, the GPI anchor acceptor peptide comprises the GPI anchor acceptor peptide sequence of CD16b comprising at least a portion, *e.g.*, at least about 10 or at least about 20 or at least about 25 consecutive residues, of the sequence: SSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTN (SEQ ID NO:1) or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions (*see* Simmons D and Seed B, 1988, Nature 333:568-570).

In a particular non-limiting embodiment, the GPI anchor acceptor peptide comprises the GPI anchor acceptor peptide sequence of CD16b comprising at least a portion, *e.g.*, at least about 10 or at least about 20 or at least about 25 consecutive

residues, of the sequence:

VSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI (SEQ ID NO:11) or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions (*see* Simmons D and Seed B, 1988, Nature 333:568-570). In certain non-limiting embodiments, the anchoring peptide does not act via GPI. In certain non-limiting embodiments, the anchoring peptide can anchor its attached protein to a cell membrane via fatty acid/diacylglycerol. In certain other non-limiting embodiments, the anchoring peptide comprises a region that can form a transmembrane domain, for example a substantially hydrophobic region and/or a region that is predicted to be a transmembrane domain by standard software, such as but not limited to TMPred. In certain embodiments, the anchoring peptide is a PD-L1 transmembrane domain.

In certain non-limiting embodiments, a nucleic acid encoding the immunomodulator molecule linked (optionally via a linker) to an anchoring peptide can be placed under the control of a promoter that is active or activatable in an oncolytic virus-infected cell, for example, a promoter of the oncolytic virus. The encoding nucleic acid can be DNA, RNA, or cDNA to conform to the nucleic acid of the viral genome into which it is inserted.

5.3.2.2. Linkers

In certain embodiments, the immunomodulator molecule can be linked directly to the anchoring peptide. Alternatively, the immunomodulator molecule can be linked to the anchoring peptide via a linker. In certain embodiments, the linker is selected from a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, a non-helical linker or a combination thereof. In certain embodiments, the immunomodulator molecule can be linked to the anchoring peptide via one or more linkers, *e.g.*, two or more, three or more or four or more.

In certain embodiments, the linker is a peptide linker. In certain embodiments, the peptide linker comprises Gly and Ser. In certain embodiments, the peptide linker can, for example and not by way of limitation, be between about 1 and about 25 or between about 5 and about 20 or between about 5 and about 15 amino acids in length. Non-limiting examples of linkers for use in the presently disclosure subject matter are disclosed in International Patent Publication WO 2017/165464 (*e.g.*, SEQ ID NOs:42, 44, 45, 75, 76, 77 and 78), the contents of which are incorporated by reference herein in its entirety.

In certain embodiments, the peptide linker comprises a flexible linker. In certain embodiments, the flexible linker can be (G4S)₃, which corresponds to GGGGSGGGGSGGGGS (SEQ ID NO:12). In a particular non-limiting embodiment, the linker linked to the anchoring peptide can comprise the amino acid sequence

5 GPAGGGGSGGGGSGGGGSVSTISSFPPGYQVSFCLVMV

LLFAVDTGLYFSVKTNI (SEQ ID NO:16) or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3

conservative amino acid substitutions. Non-limiting examples of certain GPI-anchored cytokines are provided in United States Patent Application Publication No. US

10 2003/0105054 (*e.g.*, paragraphs [0045] and [0075]) and United States Patent No.

6,277,368, the contents of which are hereby incorporated by reference in their entireties.

In certain embodiments, the peptide linker comprises a rigid linker. In certain embodiments, the rigid linker can be (A(EA₃K)₄AAA) (SEQ ID NO: 36), which

corresponds to AEAAAKEAAAKEAAAKEAAAKAAA. In certain embodiments, the

15 linker comprises the amino acid sequence SEQ ID NO:36 or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions.

5.3.2.3. Non-limiting Embodiments

In certain non-limiting embodiments, the presently disclosed subject matter

20 provides for an oncolytic virus encoding a membrane-associated protein comprising an immunomodulator molecule as set forth above linked to an anchoring peptide, optionally, via a linker.

In certain embodiments, the oncolytic virus is a herpes simplex virus, a vaccinia virus, an adenovirus or a vesicular stomatitis virus. In certain embodiments, the

25 immunomodulator molecule can be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,

IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, CXCL11,

CCL5, an IFN, IFN-alpha, IFN-alpha2, IFN-beta, IFN-gamma, a TNF, TNF-alpha, TNF-

beta, GM-CSF or a combination thereof. In certain embodiments, the immunomodulator

30 molecule is IL-2. In certain embodiments, the immunomodulator molecule is IL-23. In certain embodiments, the immunomodulator molecule is TNF-alpha.

In certain non-limiting embodiments, the anchoring peptide comprises at least a portion of any one of SEQ ID NOs:1-11, for example said portion comprising between at least about 10 or at least about 20 or at least about 25 consecutive amino acid residues. In a specific non-limiting embodiment, the anchoring peptide comprises the amino acid

sequence of SEQ ID NO:11, or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions.

5 In certain non-limiting embodiments, the immunomodulator molecule is joined to the anchoring peptide by a peptide linker between about 1 and about 25 or between about 5 and about 15 amino acids in length. In certain non-limiting embodiments, the linker comprises at least a portion of any one of SEQ ID NOs:12 and 36, for example said portion comprising between at least about 10 or at least about 20 or at least about 25 consecutive amino acid residues. In certain non-limiting embodiments, the linker
10 comprises the sequence (G4S)₃ (SEQ ID NO:12) or conservative substitutions thereof. In certain non-limiting embodiments, the linker comprises the sequence (A(EA₃K)₄AAA) (SEQ ID NO: 36) or conservative substitutions thereof.

In certain embodiments, the oncolytic virus can comprise a gene encoding a membrane-associated fusion protein that includes an immunomodulator molecule fused to
15 an anchoring peptide, *e.g.*, a GPI anchor (*e.g.*, a GPI-anchor acceptor sequence of human CD16b), via a rigid linker (alternatively referred to herein as “RGPI” or “RG”). In certain embodiments, the oncolytic virus can comprise a gene encoding a membrane-associated fusion protein that includes an immunomodulator molecule fused to an anchoring peptide, *e.g.*, a GPI anchor (*e.g.*, a GPI-anchor acceptor sequence of human
20 CD16b), via a flexible linker (alternatively referred to herein as “FGPI” or “FG”). In certain embodiments the GPI anchor sequence can be replaced with a PD-L1 transmembrane domain.

In certain embodiments, the oncolytic virus can comprise a gene encoding a membrane-associated fusion protein that includes an immunomodulator fused to a PD-L1
25 transmembrane domain, via a rigid linker. In certain embodiments, the oncolytic virus can comprise a gene encoding a membrane-associated fusion protein that includes an immunomodulator fused to a PD-L1 transmembrane domain, via a (G4S)₃ linker. In certain embodiments, the oncolytic virus can comprise a gene encoding a membrane-associated fusion protein that includes an immunomodulator fused to a PD-L1
30 transmembrane domain, via a flexible linker (alternatively referred to herein as “FPTM”).

In certain embodiments, the presently disclosed subject matter provides for an oncolytic virus, *e.g.*, a vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic acid, encoding IL-2. In certain non-limiting embodiments, the IL-2 is human IL-2. In certain non-limiting embodiments, the human IL-2 comprises at least a

portion of the amino acid sequence of SEQ ID NO:13 or conservative substitutions thereof, or said sequence having one amino acid or two amino acid variations. In certain embodiments, the IL-2 is linked to an anchoring peptide, optionally with a linker peptide between IL-2 and the anchoring peptide. In certain non-limiting embodiments, the anchoring peptide comprises at least a portion of any one of SEQ ID NOS: 1-11, 17, and 37, for example said portion comprising between at least about 10 or at least about 20 or at least about 25 consecutive amino acid residues. In certain non-limiting embodiments, the IL-2 is joined to the anchoring peptide by a peptide linker between about 1 and about 25 or between about 5 and about 15 amino acids in length. In certain embodiments, the nucleic acid encoding IL-2 is operably linked to a promoter active or activatable in an oncolytic virus-infected cell, for example, an oncolytic virus promoter (*e.g.*, a vaccinia virus promoter).

In certain non-limiting embodiments, the nucleic acid present in the genome of the oncolytic virus can encode human IL-2 (*e.g.*, comprising the amino acid sequence of SEQ ID NO:13), linked to an anchoring peptide (*e.g.*, comprising the amino acid sequence of SEQ ID NO:11) via a peptide linker (*e.g.*, comprising the amino acid sequence of SEQ ID NO:12). For example, but not by way of limitation, the nucleic acid encodes
 APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA
 TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE
 TTFMCEYADE TATIVEFLNR WITFCQSIIS TLTGPAGGGGSGGGGSGGGGS
 VSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI (SEQ ID NO:14) or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions. In certain non-limiting embodiments, said encoding nucleic acid can be operably linked to an oncolytic virus promoter. In certain embodiment, said encoding nucleic acid can be operably linked to a vaccinia promoter, for example the p7.5 e/l promoter, or the pSe/l promoter to generate a promoter/ANCHIM-encoding construct. In certain non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *tk* gene. In certain other non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *vgf* gene.

In certain non-limiting embodiments, the nucleic acid can encode human IL-2 (*e.g.*, comprising the amino acid sequence of SEQ ID NO:13), linked to an anchoring peptide (*e.g.*, comprising the amino acid sequence of SEQ ID NOS:11 and 37) via a peptide linker (*e.g.*, comprising the amino acid sequence of SEQ ID NO:12 and 36).

In certain non-limiting embodiments, said encoding nucleic acid can be operably linked to a vaccinia promoter, for example the p7.5 e/l promoter, or the pSe/l promoter to generate a promoter/ANCHIM-encoding construct. In certain non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *tk* gene. In certain
5 other non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *vgf* gene.

In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic acid, encoding TNF-alpha. In certain embodiments, TNF-alpha
10 is linked to an anchoring peptide, optionally with a linker peptide between TNF-alpha and the anchoring peptide. In certain embodiments, the nucleic acid is operably linked to a promoter active or activatable in a vaccinia virus-infected cell, for example a vaccinia virus promoter. In certain non-limiting embodiments, the TNF-alpha is human TNF-alpha. In certain non-limiting embodiments, the human TNF-alpha comprises at least an
15 immune-activating portion of SEQ ID NO:15, or said sequence having one or two amino acid variations. In certain non-limiting embodiments, the anchoring peptide comprises at least a portion of any one of SEQ ID NOS:1-11, for example said portion comprising at least between at least about 10 or at least about 20 or at least about 25 consecutive residues. In a specific non-limiting embodiment, the anchoring peptide comprises SEQ
20 ID NO:11, or that sequence bearing about 1 or about 2 amino acid substitutions, insertions or deletions, or about 1, about 2 or about 3 conservative amino acid substitutions. In certain non-limiting embodiments, the TNF-alpha is joined to the anchoring peptide by a peptide linker between about 1 and about 25 or between about 5 and about 15 amino acids in length. In certain non-limiting embodiments, the linker
25 comprises the sequence (G4S)₃ (SEQ ID NO:12). In certain non-limiting embodiments, said encoding nucleic acid can be operably linked to a vaccinia promoter, for example the p7.5 e/l promoter, or the pSE/L promoter, to generate a promoter/ANCHIM-encoding construct. In certain non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *tk* gene. In certain other non-limiting embodiments, the
30 promoter/ANCHIM-encoding construct can be inserted into the *vgf* gene. In certain non-limiting embodiments, the linker comprises the sequence GGGGSGGGGSGGGGS (SEQ ID NO:12). In certain non-limiting embodiments, the linker comprises the sequence RIGID LINKER (SEQ ID NO:36).

In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic acid, encoding IL-23p19 and IL-23p40. In certain embodiments, the IL-23p19 and IL-23p40 are linked to an anchoring peptide, optionally with a linker peptide between IL-23p40 and the anchoring peptide. In certain embodiments, the nucleic acid encoding IL-23p19 is operably linked to a promoter active or activatable in a vaccinia virus-infected cell, for example, a vaccinia virus promoter. In certain non-limiting embodiments, the oncolytic vaccinia virus, comprising, in its genome, a nucleic acid, which is a deoxyribose nucleic acid, that encodes a human homologue of IL-23p19, *e.g.*, IL-23A, and a human homologue of IL-23p40, *e.g.*, IL-12B, to generate IL-23. In certain non-limiting embodiments, the human IL-23A protein comprises at least an immune-activating portion of the sequence SEQ ID NO:18 or said sequence having one amino acid variation.

In a specific, non-limiting embodiment, the nucleic acid can encode IL-23p19 or a human homologue thereof, for example IL-23A (*e.g.*, comprising the amino acid sequence of SEQ ID NO:18), and can further encode IL-23p40, or a human homologue thereof, for example IL-12B, linked to an anchoring peptide (*e.g.*, comprising the amino acid sequence of SEQ ID NO:11 and 37) via a peptide linker (*e.g.*, comprising the amino acid sequence of SEQ ID NO:12 and 36). In certain non-limiting embodiments, said encoding nucleic acid can be operably linked to a vaccinia promoter, for example the p7.5 *e/l* promoter, or the pSe/*l* promoter to generate a promoter/ANCHIM-encoding construct. In certain non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *tk* gene. In certain other non-limiting embodiments, the promoter/ANCHIM-encoding construct can be inserted into the *vgf* gene.

In certain non-limiting embodiments, the presently disclosed subject matter provides for an oncolytic herpes simplex virus, comprising, in its genome, a nucleic acid, encoding an immunomodulator molecule linked to an anchoring peptide, optionally with a linker peptide between the immunomodulator molecule and the anchoring peptide, as described above. In certain embodiments, the nucleic acid encoding the immunomodulator molecule linked to an anchoring peptide, optionally with a linker peptide between the immunomodulator molecule and the anchoring peptide, can be placed under the control of a promoter that is active or activatable in an oncolytic herpes simplex virus infected cell, for example, a promoter of the oncolytic herpes simplex virus. The encoding nucleic acid linked to an anchoring peptide, optionally with a linker peptide

between the immunomodulator molecule and the anchoring peptide can be DNA, RNA, or cDNA to conform to the nucleic acid of the viral genome into which it is inserted.

The presently disclosed subject matter further provides for pharmaceutical compositions comprising one or more of the above-described engineered (recombinant) oncolytic viruses, for example in a physiologic buffer, and for such therapeutic compositions in solid, liquid, frozen, or lyophilized form. The presently disclosed subject matter further provides for a delivery device, for example a syringe, containing a therapeutically effective amount of such a pharmaceutical composition. Non-limiting examples of pharmaceutical compositions comprising one or more oncolytic viruses described herein are disclosed in section 5.7 below.

5.4. ONCOLYTIC VIRUS ADMINISTRATION

The oncolytic viruses disclosed herein, *e.g.*, armed oncolytic viruses, can be administered according to any known method in the art. For example, but not by way of limitation, a method for the delivery of an oncolytic virus, *e.g.*, a vaccinia virus, as described herein or a pharmaceutical composition thereof or compositions that include anti-tumor T cells isolated from cancer tissue, to cancer or tumor cells can be via intratumoral injection. In certain embodiments, alternate methods of administration can also be used, *e.g.*, intravenous, *via* infusion, parenteral, intravenous, intradermal, intramuscular, transdermal, rectal, intraurethral, intravaginal, intranasal, intrathecal, or intraperitoneal. The routes of administration can vary with the location and nature of the tumor. In certain embodiments, the route of administration can be intradental, transdermal, parenteral, intravenous, intramuscular, intranasal, subcutaneous, regional (*e.g.*, in the proximity of a tumor, particularly with the vasculature or adjacent vasculature of a tumor), percutaneous, intrathecal, intratracheal, intraperitoneal, intraarterial, intravesical, intratumoral, inhalation, perfusion, by lavage or orally. In certain embodiments, the modified virus can be administered to the patient from a source implanted in the patient.

In certain embodiments, administration of the modified virus can occur by continuous infusion over a selected period of time. In certain embodiments, an oncolytic vaccinia virus as described herein, or a pharmaceutical composition containing the same can be administered at a therapeutically effective dose by infusion over a period of about 15 mins, about 30 mins, about 45 mins, about 50 mins,

about 55 mins, about 60 minutes, about 75 mins, about 90 mins, about 100 mins, or about 120 mins or longer.

The oncolytic vaccinia virus or the pharmaceutical composition of the present disclosure can be administered as a liquid dosage, wherein the total volume of administration is about 1 ml to about 5 ml, about 5 ml to 10 ml, about 15 ml to about 20 ml, about 25 ml to about 30 ml, about 30 ml to about 50 ml, about 50 ml to about 100 ml, about 100 ml to 150 ml, about 150 ml to about 200 ml, about 200 ml to about 250 ml, about 250 ml to about 300 ml, about 300 ml to about 350 ml, about 350 ml to about 400 ml, about 400 ml to about 450 ml, about 450 ml to 500 ml, about 500 ml to 750 ml or about 750 ml to 1000 ml.

In certain embodiments, a single dose of virus can refer to the amount administered to a subject or a tumor over a 1, 2, 5, 10, 15, 20 or 24 hour period. In certain embodiments, the dose can be spread over time or by separate injection. In certain embodiments, multiple doses (*e.g.*, 2, 3, 4, 5, 6 or more doses) of the vaccinia virus can be administered to the subject, for example, where a second treatment can occur within 1, 2, 3, 4, 5, 6, 7 days or weeks of a first treatment. In certain embodiments, multiple doses of the modified virus can be administered to the subject over a period of 1, 2, 3, 4, 5, 6, 7 or more days or weeks. In certain embodiments, the oncolytic vaccinia virus or the pharmaceutical composition as described herein can be administered over a period of about 1 week to about 2 weeks, about 2 weeks to about 3 weeks, about 3 weeks to about 4 weeks, about 4 weeks to about 5 weeks, about 6 weeks to about 7 weeks, about 7 weeks to about 8 weeks, about 8 weeks to about 9 weeks, about 9 weeks to about 10 weeks, about 10 weeks to about 11 weeks, about 11 weeks to about 12 weeks, about 12 weeks to about 24 weeks, about 24 weeks to about 48 weeks, about 48 weeks or about 52 weeks, or longer. The frequency of administration of the oncolytic vaccinia virus or the pharmaceutical composition as described herein can be, in certain instances, once daily, twice daily, once every week, once every three weeks, once every four weeks (or once a month), once every 8 weeks (or once every 2 months), once every 12 weeks (or once every 3 months), or once every 24 weeks (once every 6 months).

The terms “therapeutically effective amount” or “effective amount,” as used interchangeably herein, can refer to the amount of oncolytic virus that, when administered, can be sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated. The term

“therapeutically effective amount” can also refer to the amount of oncolytic virus that is sufficient to elicit the biological or medical response of a cell, tissue, system, animal or human. An effective amount in such method can include an amount that reduces growth rate or spread of the cancer or that prolongs survival in the subject. This disclosure provides a method of reducing the growth of a tumor, which method can comprise administering, to the tumor, an effective amount of a modified virus as described above. In certain embodiments, an effective amount of a modified virus, or a pharmaceutical composition thereof, can include an amount sufficient to induce the slowing, inhibition or reduction in the growth or size of a tumor and can include the eradication of the tumor. Reducing the growth of a tumor can be manifested, for example, by reduced growth rate or a prolonged survival of a subject containing the tumor. In certain embodiments, a “therapeutically effective amount” or “effective amount” can include an amount sufficient to induce the infiltration of T cells into the tumor and/or cancer.

An effective amount of virus can be determined by methods known in the art. In certain embodiments, the virus can be administered in an amount sufficient to induce oncolysis in at least about 20% of cells in a tumor, in at least about 30% of cells in a tumor, in at least about 40% of cells in a tumor, in at least about 50% of cells in a tumor, in at least about 60% of cells in a tumor, in at least about 70% of cells in a tumor, in at least about 80% of cells in a tumor, or in at least about 90% of cells in a tumor.

In certain embodiments, the amount of virus administered can be between about 1×10^7 and 1×10^{10} infectious viral particles or plaque forming units (pfu), or between about 1×10^7 and 1×10^9 pfu/m² surface area of the subject to be treated. In certain embodiments, the virus can be administered at a dose that can comprise about 1×10^8 pfu. In certain embodiments, the amount of virus administered can be between about 1×10^3 and 1×10^{12} viral particles or pfu, or between about 1×10^5 and 1×10^{10} pfu, or between about 1×10^5 and 1×10^8 pfu, or between about 1×10^8 and 1×10^{10} pfu. In certain embodiments, the virus can be administered at a dose that can comprise about 1×10^3 pfu/dose to about 1×10^4 pfu/dose, about 1×10^4 pfu/dose to about 1×10^5 pfu/dose, about 1×10^5 pfu/dose to about 1×10^6 pfu/dose, about 1×10^7 pfu/dose to about 1×10^8 pfu/dose, about 1×10^9 pfu/dose to about 1×10^{10} pfu/dose, about 1×10^{10} pfu/dose to about 1×10^{11} pfu/dose, about 1×10^{11} pfu/dose to about 1×10^{12} pfu/dose, about 1×10^{12} pfu/dose to about 1×10^{13} pfu/dose, about 1×10^{13} pfu/dose to about 1×10^{14} pfu/dose, or

about 1×10^{14} pfu/dose to about 1×10^{15} pfu/dose. In certain embodiments, an oncolytic vaccinia virus of the presently disclosed subject matter can be administered at a dose that can comprise about 1×10^3 viral particles/dose to about 1×10^4 viral particles/dose, about 1×10^4 viral particles/dose to about 1×10^5 viral particles/dose, about 1×10^5 viral particles/dose to about 1×10^6 viral particles/dose, about 1×10^6 viral particles/dose to about 1×10^7 viral particles/dose to about 1×10^8 viral particles/dose, about 1×10^8 viral particles/dose to about 1×10^9 viral particles/dose to about 1×10^{10} viral particles/dose, about 1×10^{10} viral particles/dose to about 1×10^{11} viral particles/dose, about 1×10^{11} viral particles/dose to about 1×10^{12} viral particles/dose, about 1×10^{12} viral particles/dose to about 1×10^{13} viral particles/dose, about 1×10^{13} viral particles/dose to about 1×10^{14} viral particles/dose, or about 1×10^{14} viral particles/dose to about 1×10^{15} viral particles/dose.

5.5. METHODS OF MANUFACTURE

5.5.1. Isolation and Preparation of Tumor Infiltrated T Cells - Induced by Oncolytic Virus ("OV-induced T cells")

In certain embodiments, the presently disclosed subject matter relates to oncolytic viruses that promotes the infiltration of immune cells into the tumor microenvironment, thus becoming tumor-infiltrated immune cells induced by oncolytic virus.

In certain embodiments, the presently disclosed subject matter relates to oncolytic viruses that elicit systemic and potent anti-tumor immune cells, wherein the anti-tumor cells can be isolated from tumor tissues, expanded *ex vivo*, and administered to cancer patients for cancer treatments, *e.g.*, in the mode of adoptive T cell transfer.

In certain embodiments, the presently disclosed subject matter relates to oncolytic viruses that promote the infiltration of T cells into the tumor microenvironment, thus becoming OV-induced T cells (also referred to herein as "tumor-infiltrated T cells" or "TILs"). In certain embodiments, the oncolytic virus promotes infiltration of tumor-specific CD8+ and CD4+ T cells. In certain embodiments, the oncolytic virus promotes infiltration of activated innate immune cells. In certain embodiments, the activated innate immune cells comprise natural killer (NK) cells.

In certain embodiments, the presently disclosed subject matter relates to a method of making OV-induced T cells that comprises administering, to the subject, an effective amount of an oncolytic virus and inducing the elicitation and trafficking of T cells into the tumor tissue of the subject. Non-limiting examples of oncolytic viruses are disclosed above in section 5.1 and 5.3. In certain embodiments, the oncolytic virus can be a

vaccinia virus. For example, but not by way of limitation, the vaccinia virus can be vvDD. In certain embodiments, the oncolytic virus (*e.g.*, vvDD) encodes, in expressible form, an immunomodulator molecule. For example, but not by way of limitation, the immunomodulator molecule can be IL-2, IL-15, CXC11 and/or CCL5. In certain
5 embodiments, the presently disclosed subject matter relates to oncolytic vaccinia viruses (*e.g.*, vvDD) encoding, in expressible form, at least one secreted and/or at least one membrane-associated immunomodulator molecule, as described above. In certain non-limiting embodiments, the oncolytic virus encodes, in an expressible form, IL-2, *e.g.*, secreted or membrane-associated IL-2.

10 In certain embodiments, the method of making OV-induced T cells, further comprises isolating OV-induced T cells from the subject, *e.g.*, from the tumor of the subject. In certain embodiments, OV-induced T cells can be isolated from lymphoid and non-lymphoid tissues or from peripheral blood. In certain embodiments, OV-induced T cells can be isolated from cancer tissue. For example, the T cells can be isolated from
15 tissue by digesting the tissue and using density gradient centrifugation, *e.g.*, using a Percoll density gradient.

 In certain embodiments, the method of making OV-induced T cells, further comprises expanding the isolated OV-induced T cells *ex vivo*. In certain embodiments, during *ex vivo* expansion, the isolated OV-induced T cells can be treated with one or more
20 cytokines, lymphokines, and/or one or more agents, for example, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, IFN-alpha, IFN-alpha2, IFN-beta, IFN-gamma, TNF-alpha, TNF-beta, GM-CSF or combinations thereof. For example, but not by way of limitation, the isolated OV-induced T cells can be treated with IL-7, IL-2 and/or a GSK3b inhibitor. In certain
25 embodiments, the OV-induced T cells can be treated with IL-2. In certain embodiments, the OV-induced T cells can be treated with IL-7. In certain embodiments, the OV-induced T cells can be treated with IL-2 and IL-7. In certain, non-limiting examples the isolated T cells can be treated for about two to about 10 days, *e.g.*, about three days.

 In certain embodiments, the isolated OV-induced T cells are co-cultured with
30 dendritic and cancer cells. In certain embodiments, the OV-induced T cells can be co-cultured with cancer cells that have been infected with an oncolytic virus, *e.g.*, an oncolytic virus disclosed herein. In certain embodiments, the cancer cells can be infected with an oncolytic virus that is different than the oncolytic virus used to generate the OV-induced T cells. In certain embodiments, the isolated OV-induced T cells are co-cultured

with dendritic cells and cancer cells for about two to about 10 days, *e.g.*, about two days. In certain embodiments, the co-cultured T cells are then treated with one or more cytokines and/or one or more agents.

In certain embodiments, to quantify the ability of the oncolytic virus to promote T cell infiltration in the tumor microenvironment, isolated OV-induced T cells can be analyzed with antibodies against CD3, CD8, CD4, and 4-1BB. In certain embodiments, the oncolytic virus promotes an infiltration of CD3⁺, CD8⁺, CD4⁺, and 4-1BB⁺ T cells in the tumor microenvironment. In certain embodiments, the isolated OV-induced T cells are CD3⁺, CD8⁺, CD4⁺ and/or 4-1BB⁺. In certain embodiments, the OV-induced T cells are CD3⁺. In certain embodiments, the OV-induced T cells are CD3⁺. In certain embodiments, the OV-induced T cells are CD4⁺. In certain embodiments, the OV-induced T cells are CD8⁺. In certain embodiments, the OV-induced T cells are CD4⁺ 4-1BB⁺. In certain embodiments, the OV-induced T cells are CD8⁺ 4-1BB⁺.

In certain embodiments, the OV-induced T cells can be used for cancer therapy via adoptive T cell transfer, as described in section 5.6.1. below. In certain embodiments, the presently disclosed subject matter relates to adoptive immunotherapy, wherein the tumor-infiltrated T cells can be isolated from tumor tissues, expanded *ex vivo*, and administered to cancer patients for cancer treatments, *e.g.*, in the mode of adoptive T cell transfer. In certain embodiments, the OV-induced T cells can exert their functions to kill cancer cells and associated stromal cells. In certain embodiments, the OV-induced T cells can be transferred to the subject from which the cells were isolated. Alternatively and/or additionally, the OV-induced T cells can be transferred to a different subject. In certain embodiments, the OV-induced T cells are allogeneic.

In certain embodiments, prior to transfer of the isolated OV-induced T cells to a subject, the isolated OV-induced T cells can be analyzed for tumor specificity in a co-culture assay. In certain embodiments, the isolated OV-induced T cells are co-cultured with target cancer cells, irrelevant cancer cells or splenocytes from for about one to about 10 days, *e.g.*, about one day. In specific embodiments, the cancer cells are γ -irradiated. In certain embodiments, the isolated OV-induced T cells are co-cultured with target cancer cells, irrelevant cancer cells or splenocytes. In certain embodiments, the isolated OV-induced T cells for transfer can present specific reactivity against the target tumor cells. In certain embodiments, the specific reactivity comprises an increase in the IFN- γ expression by the isolated OV-induced T cells when they are co-cultured with target

cancer cells, compared when co-cultured with irrelevant target cancer cells or splenocytes.

5.6. METHODS OF TREATMENT

5 The present disclosure provides methods for the treatment of subjects that have cancer. In particular, the present disclosure provides methods for the treatment of a subject that has cancer that includes administering isolated OV-induced T cells to the subject that has cancer as a mode of adoptive T cell immunotherapy. The present disclosure further provides methods for the treatment of a subject that has cancer, which
10 includes the administration of oncolytic viruses that are armed with an immunomodulator molecule, *e.g.*, secreted or membrane associated.

Non-limiting examples of oncolytic viruses for use in the presently disclosed methods are disclosed above in sections 5.1, 5.3 and 5.5 above. Methods of administering oncolytic viruses is disclosed above in section 5.4 above. A subject can be
15 a human or a non-human subject. Non-limiting examples of non-human subjects include non-human primates, dogs, cats, horses, pigs, cows, mice, rats, hamsters and other rodents, rabbits, etc.

Non-limiting examples of cancers that can be treated by the disclosed methods include gastrointestinal cancer, colon carcinoma, colorectal cancer, ovarian carcinoma, mesothelioma, melanoma, breast cancer, brain cancer (*e.g.*, glioblastoma), prostate
20 cancer, cervical cancer, non-small cell lung cancer, renal carcinoma, hepatic cancer, pancreatic cancer, biliopancreatic cancer, adenocarcinoma of the liver, gastric cancer, liver cancer, peritoneal cancer, pleural cancer, hematopoietic cancer, and metastatic cancer.

25 In certain embodiments, treatment by administration of isolated OV-induced T cells or by using a modified virus can be used alone or in combination with one or immunomodulatory agents. An immunomodulatory agent can include any compound, molecule or substance capable of suppressing antiviral immunity associated with a tumor or cancer. In certain embodiments, the immunomodulatory agent can be capable of
30 suppressing innate immunity or adaptive immunity to the modified virus. Non-limiting examples of immunomodulatory agents include anti-CD33 antibody or variable region thereof, an anti-CD11b antibody or variable region thereof, a COX2 inhibitor, *e.g.*, celecoxib, cytokines, such as IL-12, GM-CSF, IL-2, IFN3 and IFN γ , and chemokines, such as MIP-1, MCP-1 and IL-8. In certain embodiments, the immunomodulatory agent

includes immune checkpoint inhibitors such as, but not limited to, anti-CTLA4 antibodies, anti-PD-1 antibodies, anti-PDL1 antibodies and TLR agonists (*e.g.*, Poly I:C). In certain embodiments, the checkpoint inhibitors can include molecules and/or compounds that inhibit and/or reduce PD-1, PD-L1 and/or CTLA4 activity and/or function. In certain embodiments, the immunomodulatory agent can be administered systemically or locally.

“In combination with,” as used herein, means that a virus, such as an oncolytic vaccinia virus as described herein or a pharmaceutical composition thereof, and the additional therapy, are administered to a subject as part of a treatment regimen or plan. In certain embodiments, being used in combination does not require that the oncolytic virus and the one or more agents are physically combined prior to administration or that they be administered over the same time frame. For example, and not by way of limitation, the oncolytic virus and the one or more agents can be administered concurrently to the subject being treated, or can be administered at the same time or sequentially in any order or at different points in time. In certain embodiments, methods of the present disclosure can include the administration of immunomodulatory agent prior to administration of an oncolytic virus, *e.g.*, an oncolytic virus that comprises a nucleic acid that encodes an immunomodulatory molecule, *e.g.*, IL-2. For example, but not by way of limitation, the immunomodulatory agent can be IL-2, *e.g.*, administered systemically or locally. In certain embodiments, the methods of the presently disclosed subject matter can include promoting an initial immune response in the subject to be treated by administering an oncolytic virus, disclosed herein, *e.g.*, an oncolytic virus that comprises a nucleic acid that encodes an immunomodulatory molecule, *e.g.*, IL-2, and/or the administration of immunomodulatory agent, *e.g.*, IL-2.

In certain embodiments, the methods of the presently disclosed subject matter can comprise administering one or more isolated OV-induced T cells, a virus as disclosed herein or a pharmaceutical composition thereof, followed by, preceded by or in combination with one or more additional therapies. Non-limiting examples of the such therapies can include chemotherapy, radiation, oncolytic viral therapy with an additional virus, treatment with immunomodulatory proteins, an anti-cancer agent or any combinations thereof. Anti-cancer agents can include, but are not limited to, chemotherapeutic agents, radiotherapeutic agents, cytokines, immune checkpoint inhibitors, anti-angiogenic agents, apoptosis-inducing agents, anti-cancer antibodies and/or anti-cyclin-dependent kinase agents. In certain embodiments, the cancer therapies

can include chemotherapy, biological therapy, radiotherapy, immunotherapy, hormone therapy, anti-vascular therapy, cryotherapy, toxin therapy and/or surgery or combinations thereof.

Certain non-limiting embodiments of the presently disclosed subject matter provide for methods of treating cancer where the cancer is an early stage cancer. Certain non-limiting embodiments of the presently disclosed subject matter provide for methods of treating cancer as set forth above where the cancer is not an early stage cancer. For example, but not by way of limitation, the cancer can be a late stage cancer. In certain embodiments, late stage cancer can refer to a cancer that is no longer be limited to the organ of origin: *e.g.*, it may have locally extended beyond the organ of origin or may have metastasized to another site in the body. In certain embodiments, a late stage cancer can be a Grade III cancer. In certain non-limiting embodiments, the presently disclosed subject matter can be used to treat locally invasive or metastatic forms of cancer.

In certain embodiments, the presently disclosed subject matter can be applied to treatment of colon cancer that is stage T3 or higher and/or M1 or higher. In certain embodiments, the presently disclosed subject matter can be applied to treatment of ovarian cancer that is stage 1C or higher. In another certain non-limiting embodiment, the presently disclosed subject matter can be applied to the treatment of mesothelioma that is stage 2 or stage 3 or higher. In certain embodiments, the presently disclosed subject matter can be applied to the treatment of melanoma that is Stage III or higher.

5.6.1. Adoptive T-cell Immunotherapy

The presently disclosed subject matter provides for methods of treating a subject suffering from a cancer with isolated OV-induced T cells. In certain embodiments, the OV-induced T cells are produced as described above in section 5.5. above. In certain embodiments, the OV-induced T cells can be transferred to the subject from which the cells were isolated. Alternatively and/or additionally, the OV-induced T cells can be transferred to a different subject.

The presently disclosed subject matter provides for an adoptive T-cell immunotherapy, comprising isolating the OV-induced T cells, expanding them *ex vivo*, and transferring them back to a subject suffering from a cancer. Methods for adoptive T cell transfer are disclosed in US 2003/0170238, the contents of which are incorporated herein by reference.

In certain embodiments, the method of treating a subject suffering from a cancer comprises administering a therapeutically effective amount of OV-induced T cells to the

subject. In certain embodiments, the OV-induced T cells were isolated from a different subject. In certain embodiments, the OV-induced T cells were isolated from the subject that is to be treated with the OV-induced T cells.

5 In certain embodiments, the method of treating a subject suffering from a cancer comprises administering, to the subject, an effective amount of an oncolytic virus, inducing the elicitation of potent antitumor T cells, promoting the trafficking of the induced potent antitumor T cells into the tumor tissues to generate OV-induced T cells, isolating the OV-induced T cells and administering the isolated OV-induced T cells to the subject.

10 In certain embodiments, the method of treating a subject suffering from a cancer comprises (a) administering, to the subject, an effective amount of an oncolytic virus; (b) isolating OV-induced T cells; (c) expanding the tumor-infiltrated T cells; and (d) transferring the tumor-infiltrated T cells to the subject suffering from cancer.

15 In certain non-limiting embodiments, the isolated OV-induced T cells treated with one or more cytokines and/or one or more agents and expanded *ex vivo*, as described above, are then introduced, *e.g.*, intraperitoneally (*i.p.*), into a cancer patient. In certain embodiments, the isolated OV-induced T cells are administered intratumorally in a cancer patient.

20 Non-limiting examples of oncolytic viruses for use in the disclosed methods are described above. For example, but not by way of limitation, the oncolytic virus can be a herpes simplex virus, a vaccinia virus, an adenovirus or a vesicular stomatitis virus. In certain embodiments, the oncolytic virus can be the Western Reserve strain of vaccinia virus. In certain embodiments, the oncolytic virus is the vvDD vaccinia virus. In certain embodiments, the oncolytic virus is a vaccinia virus, *e.g.*, vvDD. In certain non-limiting
25 embodiments, the oncolytic virus can comprise, in its genome, a nucleic acid, encoding an immunomodulator molecule. In certain embodiments, the presently disclosed subject matter relates to oncolytic vaccinia viruses encoding, in expressible form, at least one secreted and/or at least one membrane-associated immunomodulator molecule comprising an immunomodulator molecule linked to a membrane attachment domain, *e.g.*, anchoring
30 peptide, as described above. In certain embodiments, the immunomodulator molecule can be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, CXCL11, CCL5, an IFN, IFN-alpha, IFN-alpha2, IFN-beta, IFN-gamma, a TNF, TNF-alpha, TNF-beta, GM-CSF or a combination thereof. In certain embodiments, the immunomodulator molecule is IL-2. In certain

embodiments, the immunomodulator molecule is IL-23. In certain embodiments, the immunomodulator molecule is TNF-alpha. In certain embodiments, the immunomodulator molecule is CXC11. In certain embodiments, the immunomodulator molecule is CCL5. In certain embodiments, the immunomodulator molecule is IL-15. In certain embodiments, the oncolytic virus, *e.g.*, vaccinia virus, can comprise a nucleic acid that encodes IL-2. In certain embodiments, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2. In certain embodiments, the oncolytic virus is the vvDD vaccinia virus that comprises a nucleic acid that encodes IL-2. In certain embodiments, the oncolytic virus, *e.g.*, vaccinia virus, can comprise a nucleic acid that encodes IL-2 linked to an anchoring peptide. In certain embodiments, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide. In certain embodiments, the oncolytic virus is the vvDD vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide. In certain embodiments, the IL-2 is linked to the anchoring peptide via a rigid linker. For example, and not by way of limitation, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide via a rigid linker, *e.g.*, a linker comprising the (A(EA₃K)₄AAA) linker. In certain embodiments, the oncolytic virus is the vvDD vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide via a rigid linker, *e.g.*, a linker comprising the (A(EA₃K)₄AAA) linker.

In certain non-limiting embodiments, prior to the T cell transfer, cancer patients can be administered another cancer therapy, disclosed above. In certain non-limiting embodiments, after to the T cell transfer, cancer patients can be administered another cancer therapy, disclosed above. For example, and not by way of limitation, the cancer therapies can include chemotherapy, biological therapy, radiotherapy, immunotherapy, hormone therapy, anti-vascular therapy, cryotherapy, toxin therapy and/or surgery or combinations thereof. In certain non-limiting embodiments, a cancer patient can be administered one or more exogenous cytokines and one or more agents, *e.g.*, immunomodulatory agents, prior to the T-cell transfer. In certain non-limiting embodiments, a cancer patient can be administered one or more exogenous cytokines and one or more agents after the T-cell transfer. In certain embodiments, the cytokines and/or agents can be locally or systemically administered. In certain embodiments, the cytokines

and/or agents are locally administered. For example, and not by way of limitation, a cancer patient can receive exogenous IL-2 before and/or after T cell transfer.

For example, and not by way of limitation, a cancer patient can receive exogenous IL-2 after T cell transfer.

5 In certain embodiments, the subject administered the OV-induced T cells of the presently disclosed subject matter can undergo radiation therapy prior and/or after to administration of the OV-induced T cells. For example, and not by way of limitation, the radiation dose can be about 100 Rads (1 Gy) to about 500 Rads (5 Gy), about 5,000 Rads (50 Gy) to about 100,000 Rads (1000 Gy), or about 50,000 Rads (500 Gy), or other
10 appropriate doses within the recited ranges. “Gy” as used herein can refer to a unit for a specific absorbed dose of radiation equal to 100 Rads. Gy is the abbreviation for “Gray.”

5.6.2. Treatment With Armed Oncolytic Viruses

 The presently disclosed subject matter further provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective
15 amount of an oncolytic virus, *e.g.*, an armed oncolytic virus, disclosed herein. Non-limiting examples of oncolytic viruses, *e.g.*, armed oncolytic viruses, for use in the presently disclosed methods are disclosed above in sections 5.1., 5.3., and 5.5. above. Methods of administering oncolytic viruses is disclosed above in section 5.4 above.

 In certain embodiments, the oncolytic virus can be a herpes simplex virus, a
20 vaccinia virus, an adenovirus or a vesicular stomatitis virus that comprises, in its genome, a nucleic acid encoding an immunomodulator molecule as described herein. In certain embodiments, the oncolytic virus can be the Western Reserve strain of vaccinia virus that comprises, in its genome, a nucleic acid encoding an immunomodulator molecule as described herein. In certain embodiments, the oncolytic virus is the vvDD vaccinia virus
25 that comprises, in its genome, a nucleic acid encoding an immunomodulator molecule as described herein. In certain embodiments, the oncolytic encodes, in expressible form, at least one secreted immunomodulator molecule and/or at least one membrane-associated immunomodulator molecule, as described above. In certain embodiments, the immunomodulator molecule can be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
30 IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, CXCL11, CCL5, an IFN, IFN-alpha, IFN-alpha2, IFN-beta, IFN-gamma, a TNF, TNF-alpha, TNF-beta, GM-CSF or a combination thereof. In certain embodiments, the immunomodulator molecule is IL-2. In certain embodiments, the immunomodulator molecule is IL-23. In certain embodiments, the immunomodulator molecule is TNF-alpha. In certain

embodiments, the immunomodulator molecule is CXC11. In certain embodiments, the immunomodulator molecule is CCL5. In certain embodiments, the immunomodulator molecule is IL-15. In certain embodiments, the oncolytic virus, *e.g.*, vaccinia virus, can comprise a nucleic acid that encodes IL-2. In certain embodiments, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2. In certain embodiments, the vvDD vaccinia virus that comprises a nucleic acid that encodes IL-2. In certain embodiments, the oncolytic virus, *e.g.*, vaccinia virus, can comprise a nucleic acid that encodes IL-2 linked to an anchoring peptide. In certain embodiments, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide. In certain embodiments, the IL-2 is linked to the anchoring peptide via a rigid linker. For example, and not by way of limitation, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide via a rigid linker, *e.g.*, a linker comprising the (A(EA₃K)₄AAA) linker. In certain embodiments, the oncolytic virus is the vvDD vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide via a rigid linker, *e.g.*, a linker comprising the (A(EA₃K)₄AAA) linker.

The presently disclosed subject matter provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an armed oncolytic virus, *e.g.*, an oncolytic virus encoding, in expressible form, an immunomodulator molecule, as described above. In certain embodiments, the administration of the oncolytic virus results in the secretion of the immunomodulator molecule from cells infected with the virus. In certain embodiments, the immunomodulator molecule is IL-2.

The presently disclosed subject matter provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus encoding, in expressible form, a membrane-associated protein comprising an immunomodulator molecule linked to an anchoring peptide, as described above. In certain embodiments, the immunomodulator molecule is IL-2.

In certain embodiments, the presently disclosed subject matter provides methods of inhibiting the growth and/or proliferation of and/or promoting the death of a cancer cell of a subject comprising administering to the subject a therapeutically effective amount of an oncolytic vaccinia virus described herein.

In certain embodiments, the presently disclosed subject matter provides methods of inhibiting the growth of a tumor of a subject comprising administering to the subject a therapeutically effective amount of an oncolytic vaccinia virus described herein.

5 The present invention further provides a method of reducing or inhibiting the growth of a tumor comprising administering to the tumor and/or contacting the tumor with a therapeutically effective amount of an oncolytic vaccinia virus described herein.

In certain embodiments, the presently disclosed subject matter provides methods for lengthening the period of survival of a subject having a cancer comprising
10 administering to the subject a therapeutically effective amount of an oncolytic vaccinia virus described herein. In certain embodiments, the period of survival of the subject having cancer is lengthened by about 1 month, about 2 months, about 4 months, about 6 months, about 8 months, about 10 months, about 12 months, about 14 months, about 18 months, about 20 months, about 2 years, about 3 years, about 5 years or more.

15 In certain embodiments, the presently disclosed subject matter further provides methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus encoding, in expressible form, an immunomodulator molecule, which can be secreted from infected cells, and inducing the elicitation of potent antitumor T cells.

20 The presently disclosed subject matter also provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus encoding, in expressible form, a membrane-associated protein comprising an immunomodulator molecule linked to a heterologous anchoring peptide as described above, promoting the trafficking of the induced potent antitumor T
25 cells into the tumor tissues where they would exert their cytotoxicity to cancer cells and associated stromal cells, thus displaying antitumor functions.

The presently disclosed subject matter also provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus encoding, in expressible form, a membrane-associated
30 protein comprising an immunomodulator molecule linked to an anchoring peptide as described above, inducing the elicitation of potent antitumor T cells, and promoting the trafficking of the induced potent antitumor T cells into the tumor tissues where they would exert their cytotoxicity to cancer cells and associated stromal cells, thus displaying antitumor functions.

Certain non-limiting embodiments of the presently disclosed subject matter provide for methods of treating cancer as set forth above where the cancer is an early stage cancer. Certain non-limiting embodiments of the presently disclosed subject matter provide for methods of treating cancer as set forth above where the cancer is not an early stage cancer. Certain non-limiting embodiments of the presently disclosed subject matter provide for methods of treating cancer as set forth above where the cancer is a late stage cancer.

In certain embodiments, the presently disclosed subject matter provides for methods of treating cancer when there is increased tumor burden and/or edema in liver and/or kidneys, increased presence of immunosuppressive CD4⁺Foxp3⁺, CD4⁺PD-1⁺ and CD8⁺PD-1⁺ T cells, G-MDSC and PD-L1⁺ cells, and/or decreased presence of NK cells, or when there is increased PD-1, PD-L1, TGF- β and VEGF expression in the tumor microenvironment, compared with the early-stage cancer.

In certain embodiments, the administration of an effective amount of an oncolytic virus results in increased levels of IFN- γ , Granzyme B, perforin and TGF- β , IL-10 and/or decreased levels of angiogenesis markers, *e.g.*, CD105 and VEGF, in tumors that received an oncolytic virus encoding, in expressible form, a membrane-associated protein comprising an immunomodulator molecule linked to an anchoring peptide as described above, compared with tumors received the oncolytic virus encoding, in expressible form, a membrane-associated protein comprising an immunomodulator molecule that can be secreted.

In certain embodiments, the recently disclosed subject matter provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus, described herein, optionally in combination with a checkpoint inhibitor, *e.g.*, an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody.

In certain embodiments, the recently disclosed subject matter provides for methods of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus, described herein, optionally in combination with an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody. For example, and not by way of limitation, a method disclosed herein can include administering, to the subject, an effective amount of an oncolytic virus that comprises a nucleic acid that encodes IL-2 in combination with an anti-PD-1 antibody or

an anti-PD-L1 antibody. In certain embodiments, a method disclosed herein can include administering, to the subject, an effective amount of an oncolytic virus that comprises a nucleic acid that encodes IL-2 in combination with an anti-CTLA-4 antibody. In certain embodiments, the method of treating a subject suffering from a cancer, comprising
5 administering, to the subject, an effective amount of a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2, in combination with an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody.

In certain embodiments, the presently disclosed subject matter also provides for methods of treating a subject suffering from a cancer, comprising administering, to the
10 subject, an effective amount of an oncolytic virus encoding, in expressible form, a membrane-associated protein comprising an immunomodulator molecule linked to an anchoring peptide as described above, in combination an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4 antibody. For example, and not by way of limitation, a method disclosed herein can include administering, to the subject, an effective amount
15 of an oncolytic virus that comprises a nucleic acid encoding a membrane-associated protein comprising IL-2 linked to an anchoring peptide in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, a method disclosed herein can include administering, to the subject, an effective amount of an oncolytic virus that comprises a nucleic acid encoding a membrane-associated protein comprising IL-2 linked
20 to an anchoring peptide in combination with an anti-CTLA-4 antibody. In certain embodiments, the method of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide, in combination with an anti-PD-1 antibody, an anti-PD-L1 antibody and/or an anti-CTLA-4
25 antibody. In certain embodiments, the IL-2 is linked to the anchoring peptide via a rigid linker. For example, and not by way of limitation, the oncolytic virus is a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 linked to an anchoring peptide via a rigid linker, *e.g.*, a linker comprising the (A(EA₃K)₄AAA) linker.

30 In certain embodiments, methods of the presently disclosed subject matter can include depletion of Natural killer (NK) cells, CD8⁺ T cells and/or CD4⁺ T cells. In certain embodiments, methods of the presently disclosed subject matter can include neutralization of circulating IFN- γ . For example, but not by way of limitation, a method

of the presently disclosed subject matter can include administering to a subject an oncolytic virus, as disclosed herein, and the depletion of CD8⁺ T cells, NK cells and/or CD4⁺ T within the subject and/or the neutralization of circulating IFN- γ within the subject. In certain embodiments, depletion and/or neutralization can be obtained by using
5 antibodies, *e.g.*, antibodies to CD8, CD4, NK1.1 and/or IFN- γ . In certain embodiments, a method for treating a subject suffering from a cancer can comprise administering, to the subject, an effective amount of an oncolytic virus that comprises a nucleic acid that encodes IL-2 and the deletion of NK cells. For example, and not by way of limitation, the method can include administering, to the subject, an effective amount of a Western
10 Reserve strain of vaccinia virus that comprises a nucleic acid that encodes IL-2 and the deletion of NK cells, *e.g.*, by the administration of an anti-NK1.1 antibody. In certain embodiments, a method for treating a subject suffering from a cancer can comprise administering, to the subject, an effective amount of an oncolytic virus that comprises a nucleic acid encoding a membrane-associated protein comprising an immunomodulator
15 linked to an anchoring peptide and the deletion of NK cells. In certain embodiments, a method disclosed herein can include administering, to the subject, an effective amount of an oncolytic virus that comprises a nucleic acid encoding a membrane-associated protein comprising IL-2 linked to an anchoring peptide and the deletion of NK cells. For example, and not by way of limitation, the method can include administering, to the
20 subject, an effective amount of a Western Reserve strain of vaccinia virus that comprises a nucleic acid that encodes a membrane-associated protein comprising IL-2 linked to an anchoring peptide and the deletion of NK cells, *e.g.*, by the administration of an anti-NK1.1 antibody.

In certain embodiments, the subject suffers from an early stage cancer. In certain
25 embodiments, the cancer is not an early stage cancer. In certain embodiments, the subject suffers from a late stage cancer.

5.7. PHARMACEUTICAL COMPOSITIONS

The present disclosure further provides pharmaceutical compositions that include one or more isolated OV-induced T cells isolated from cancer tissue.

The present disclosure further provides pharmaceutical compositions comprising the modified viruses disclosed herein. In certain embodiments, the pharmaceutical compositions containing a modified virus, such as an oncolytic

vaccinia virus, as described herein, can be prepared as solutions, dispersions in glycerol, liquid polyethylene glycols, and any combinations thereof in oils, in solid dosage forms, as inhalable dosage forms, as intranasal dosage forms, as liposomal formulations, dosage forms comprising nanoparticles, dosage forms comprising microparticles, polymeric dosage forms, or any combinations thereof.

Pharmaceutical compositions are formulated relative to the particular administration route. For example, and not by way of limitation, pharmaceutical compositions that can be administered parenterally, intravenously, intradermally, intramuscularly, transdermally or intraperitoneally are described in U.S. Patent Nos. 5,543,158, 5,641,515 and 5,399,363, the contents of which are incorporated by reference herein in their entireties.

In certain embodiments, a pharmaceutical composition as described herein can comprise a pharmaceutically acceptable carrier, *e.g.*, an excipient. "Pharmaceutically acceptable," as used herein, includes any carrier which does not interfere with the effectiveness of the biological activity of the active ingredients and/or that is not toxic to the patient to whom it is administered. An excipient can be an excipient described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986). Non-limiting examples of suitable excipients can include a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a chelator, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener and a coloring agent.

In certain embodiments, an excipient can be a buffering agent. Non-limiting examples of suitable buffering agents can include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate. As a buffering agent, sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium glucomate, aluminium hydroxide, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide and other calcium salts or combinations thereof can be used in a pharmaceutical formulation.

5.8. KITS

The present disclosure further provides kits that comprise one or more of the disclosed oncolytic viruses described herein. In embodiments, this disclosure provides for a kit for administering a modified virus as described herein. In certain embodiments, a kit of this disclosure can include a modified virus or a pharmaceutical composition comprising a modified virus as described above. In embodiments, this disclosure provides for a kit comprising one or more OV-induced T cells. In certain embodiments, a kit of this disclosure can further include one or more components such as instructions for use, devices and additional reagents, and components, such as tubes, containers and syringes for performing the methods disclosed above.

In certain embodiments, a kit of this disclosure can include instructions for use, a device for administering the modified virus to a subject, or a device for administering an additional agent or compound to a subject. For example, and not by way of limitation, the instructions can include a description of the modified virus and, optionally, other components included in the kit, and methods for administration, including methods for determining the proper state of the subject, the proper dosage amount and the proper administration method for administering the modified virus. Instructions can also include guidance for monitoring the subject over duration of the treatment time.

In certain embodiments, a kit of this disclosure can include a device for administering the modified virus to a subject. Any of a variety of devices known in the art for administering medications and pharmaceutical compositions can be included in the kits provided herein. For example, and not by way of limitation, such devices include, a hypodermic needle, an intravenous needle, a catheter, a needle-less injection device, an inhaler and a liquid dispenser, such as an eyedropper. In certain embodiments, a modified virus to be delivered systemically, for example, by intravenous injection, can be included in a kit with a hypodermic needle and syringe.

In certain embodiments, this disclosure provides a kit for isolating tumor infiltrated T cells - induced by oncolytic virus ("OV-induced T cells") from a subject with cancer after administering a modified virus as described herein. The present disclosure
5 further provides kits that comprise isolated OV-induced T cells expanded according to the methods described herein. In certain embodiments, the OV-induced T cells are cryogenically frozen. Alternatively and/or additionally, the OV-induced T cells are provided in culture medium. In certain embodiments, the kit can provide isolated T cells and further provide for dendritic cells and cancer cells, and/or one or more cytokines

and/or one or more agents to treat T cells, including, for example, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, IFN-alpha, IFN-alpha2, IFN-beta, or IFN-gamma, TNF-alpha, TNF-beta, and GM-CSF.

5 In certain embodiments, a kit of the present disclosure can include one or more additional agents that can be administered in combination with an oncolytic virus and/or isolated OV-induced T cells. For example, but not by way of limitation, a kit can include a cytokine, *e.g.*, IL-2, and/or an anti-PD-1 and/or an anti-PD-L1 antibody.

10 In certain embodiments, a kit of this disclosure can provide a device for isolating T cells from a subject after administering the modified virus to the subject, or a device for transferring the treated T cells into a subject. For example, and not by way of limitation, a kit of this disclosure can provide instructions including a description of isolating OV-induced T cells and methods for transferring the treated T cells into a patient, including methods for determining the proper state of the subject, the proper dosage amount and the proper administration method for transferring the treated T cells. In certain embodiments, 15 a kit of this disclosure can include instructions for use, a device for administering the modified virus to a subject, and/or a device for administering an additional agent or compound to a subject, and/or a device for isolating the OV-induced T cells. For example, and not by way of limitation, the instructions can include a description of the 20 modified virus and, optionally, other components included in the kit, and methods for administration, including methods for determining the proper state of the subject, the proper dosage amount and the proper administration method for administering the modified virus. Instructions can also include a description of isolating the OV-induced T cells, methods of treating the isolated T cells, and methods of transferring the treated T 25 cells into a patient. Instructions can also include guidance for monitoring the subject over duration of the treatment time.

6. EXAMPLE 1: ONCOLYTIC VACCINIA VIRUS EXPRESSING
MEMBRANE-ATTACHED IL-2 DISPLAYED POTENT ANTITUMOR EFFICACY
30 AND REDUCED TOXICITY

An oncolytic vaccinia virus, vvDD (or VVDD), as described in United States Patent No. 7,208,313, the disclosure of which is incorporated by reference herein in its entirety, was engineered to express murine IL-2 (“mIL-2”) by inserting an mIL-2 encoding nucleic acid, under the control of the vaccinia p7.5e/l promoter, in the viral *tk*

gene, to produce virus denoted “vvDD-mIL-2,” which results in the secretion of mIL-2 from infected cells. The antitumor efficacy of this IL-2-armed virus was tested in mouse models of colon cancer, ovarian cancer, and mesothelioma, created by inoculating mice with MC38-luc, ID8-luc, or AB12-luc tumor cells, respectively, where the cells are
 5 labeled with luciferase (“luc”) to enable monitoring of tumor development. Using an experimental scheme shown in FIGURE 1A, 5.0e5 tumor cells were inoculated subcutaneously on day 0, and then, on day 5, mice were administered either PBS or 1.0e8 pfu of vvDD-IL-2 or, as a control, vvDD unarmed with mIL-2. The number of mice in each test group was 10 +/-4. Survival of the mice was monitored and the results are
 10 shown in FIGURES 1B-D; in each case vvDD-mIL-2 prolonged survival substantially relative to the controls.

However, if tumors were allowed to progress in the mice prior to virus treatment, survival of vvDD-mIL-2 treated mice was poorer than controls. As shown in FIGURE 2A, when mIL-2-armed virus was administered nine days after MC38-luc (colon cancer)
 15 tumor cell inoculation, the recipient mice died within one week (FIGURE 2B). As the tumor burden of these mice would be comparable to the control animals in this study, it is inferred that the animals died from toxic effects of secreted IL-2.

To mitigate the potential toxic effects of IL-2, an oncolytic vaccinia virus was engineered to express, in an infected tumor cell, membrane anchored IL-2. FIGURE 3A
 20 shows a schematic diagram of a portion of the engineered vvDD virus, in which mIL-2 encoding nucleic acid, fused in-frame to nucleic acid encoding a (G4S)₃ linker and a GPI anchoring peptide having the sequence
 GPAGGGGSGGGGSGGGGSVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTN
 I (SEQ ID NO:16), all operably linked to the p7.5e/l promoter, is inserted in the *tk* gene to
 25 produce virus denoted “vvDD-mIL-2-GPI”. Also disrupting the *tk* gene is a gene encoding yellow fluorescent protein (“YFP”) operably linked to the pSe/l promoter, and transcribed in the opposite direction as mIL-2, to aid in detecting virus-infected cells. When tested in MC38 colon cancer and B16 melanoma cell lines, vvDD-mIL-2-GPI expressed mIL-2 that was mostly retained on the membrane of infected cells, whereas
 30 mIL-2 expressed by vvDD-mIL-2 was not, as demonstrated by flow cytometry (FIGURES 4A-B). The infected cells were gated by YFP and then analyzed for IL-2 expression on the gated YFP+ cells. FIGURE 5A-B presents the expression intensity of IL-2 on the cell membrane. These data clearly demonstrated that vvDD-mIL-2-GPI expressed a lot more membrane-anchored IL-2 on the infected cancer cells.

FIGURE 6 shows the results of an experiment comparing “unarmed” vvDD (parental virus) with vvDD-mIL-2 and vvDD-mIL-2-GPI. Mice were administered either PBS or (unarmed) vvDD, vvDD-mIL-2, or vvDD-mIL-2-GPI (at a dose of 1.0×10^8 pfu) 5 days after tumor cell inoculation. As shown in FIGURE 6, PBS control-treated mice died within about 20 days after tumor cell inoculation and most mice treated with unarmed vvDD died within about 30 days of tumor inoculation (all mice in this group died by 43 days), but after 50 days all mice treated with vvDD-mIL-2 were still alive and more than 80 percent of mice treated with vvDD-mIL-2-GPI were alive, indicating that the “anchored” IL-2 retained beneficial IL-2 function (n= 8).

FIGURE 7 compares IL-2-related toxic effects in mice treated with 2.0×10^8 pfu (2.0×10^8 pfu) of either vvDD-mIL-2 or vvDD-mIL-2-GPI 9 days after inoculation with MC38-luc cells. Five days after viral treatment, more than 80 percent of mice treated with vvDD-mIL-2 had died, whereas all vvDD-mIL-2-GPI-treated mice survived (n= 13-15).

7. EXAMPLE 2: ADOPTIVE TRANSFER OF TUMOR INFILTRATED T CELLS – INDUCED BY ONCOLYTIC VIRUS (“OV-INDUCED T CELLS”) LED TO SIGNIFICANT THERAPEUTIC EFFECTS IN SYNGENEIC C57BL/6 MICE BEARING PERITONEAL MC38 TUMOR.

This Example provides studies of oncolytic vaccinia viruses expressing membrane-associated forms of immunostimulatory cytokines.

B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cancer cells and divided into required groups according to tumor growth condition based on live animal IVIS imaging 7 days post tumor cell injection. Grouped mouse were intraperitoneally injected with 5×10^6 T cells per 100 μ l or 100 μ l PBS as a control. T cells were generated by intratumoral vvDD-IL-2-GPI (1.0×10^8 pfu) injection into MC38 s.c. tumor bearing mouse. Ten days post virus-treatment tumors were harvested and T-cells were separated using CD90.2 beads (Miltenyl Biotec, CA, USA). T-cells were co-cultured with α DC-MC38 for 2 days. On day 2, IL-2 (4ng/ml) and IL-7 (5ng/ml) or additionally GSK3b-inhibitor (7 μ M) were added. On day 5, T-cells have been transferred intraperitoneal (i.p.) injection into MC38-luc tumor bearing mouse. Prior to T cell transfer, treated mouse received 5Gy of sublethal irradiation to mimic lymphodepletion similar to clinical protocols. All treated mouse received exogenous cytokine support of IL-2 (100,000

IU/mouse i.p. for 3 days every 12h). FIGURE 8A shows the timeline of the experimental setup.

As shown in FIGURE 8B, 100% of the tumor-bearing mice survived at least 100 days post-inoculation when administered OV-induced T cells that were treated *ex vivo* with IL-2, IL-7 and GSK3b-inhibitor and about 50% of the tumor-bearing mice survived at least 100 days post-inoculation when administered OV-induced T cells that were treated *ex vivo* with IL-2 and IL-7. Live images of the mice with MC38-luc tumors at day 21 post treatment are shown in FIGURE 8C and at day 28 post treatment in FIGURE 8D. As shown in FIGURE 8, oncolytic vaccinia viruses expressing novel forms of immunostimulatory cytokines (such as membrane-associated) can induce potent tumor-specific T cells, and promote the trafficking of such T cells into tumor tissues where they exert their functions against tumor growth. In addition, OV-induced T cells can be isolated and expanded *ex vivo* under appropriate conditions. When these cultured and expanded tumor-specific T cells were infused back to a second tumor-bearing mice, they displayed potent anti-tumor activity in MC38 colon tumor model in syngeneic mice. The present approach demonstrated that oncolytic virus-elicited and enriched anti-tumor T cells can be utilized for cancer therapy.

8. EXAMPLE 3: DISPLAYING MEMBRANE ASSOCIATED INTERLEUKIN-2 RIGIDLY WITH POTENT EFFICACY AND HIGH SAFETY.

8. 1. Introduction

Pleiotropic cytokine interleukin-2 (IL-2) is an established cancer therapeutic agent, whereas its clinical application has been limited for the severe life-threatening side effects followed by the systemic use of high dose of IL-2¹⁻⁴. Considerable efforts have been devoted to developing IL-2 variants, such as IL-2-fusion proteins, IL-2/anti-IL-2 antibody complexes and “superkines,” or chemical modified IL-2, to extend *in vivo* half-life and improve biological activity and safety⁵⁻¹³. The present Example discloses a new form of IL-2 immunotherapy through local delivery of a cell membrane associated IL-2 in tumor bed by tumor-targeted oncolytic vaccinia virus. Displaying IL-2 either flexibly or rigidly on the cell membrane cured mice with established early-stage peritoneal colon cancer, an effect similar to delivering secreted IL-2 by vaccinia virus. While secreted IL-2 delivered by vaccinia virus led to high mortality at the late-stage tumor model during the virus replication period, displaying IL-2 rigidly on cell membrane significantly enhanced the survival of mice with late-stage peritoneal colon cancer. Displaying IL-2

rigidly on the cell membrane led to profound changes in the immune status of tumor microenvironment, which made it feasible to combine anti-PD-1/PD-L1 Ab to cure most mice with late-stage peritoneal colon cancer. These findings show that the new form of IL-2 immunotherapy can be translatable to the clinic for cancer treatment.

5 Virus-delivered secreted IL-2 has been suggested to have the potential to treat established tumors in mouse models (FIGURE 1)¹⁴. To reduce the severe toxic side effects caused by systemic use of high dose of IL-2 and to treat pleural, peritoneal, hematopoietic or metastatic cancer, oncolytic vaccinia virus vvDD was used. Treating pleural, peritoneal, hematopoietic or metastatic cancer by intratumoural virus injection
10 can be difficult. Using oncolytic vaccinia virus which has been approved safe, to deliver membrane-associated IL-2 to treat peritoneal colon cancer, since membrane-associated cytokines have been suggested to retain on membrane without obvious compromised cytokine function¹⁵⁻¹⁷. An approach using oncolytic vaccinia virus vvDD can result in the use of fewer viruses and can cause less side effects.

15 8.2 Methods

Mice and cell lines. Female C57BL/6 (B6 in short) and BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed in specific pathogen-free conditions in the University of Pittsburgh animal facility. All animal studies were approved by the Institutional Animal Care and Use Committee. Mouse
20 colon cancer MC38-luc, ovarian cancer ID8-luc, mesothelioma AB12-luc were generated as described previously³¹. Mouse melanoma B16 was obtained from ATCC. All cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mL L-glutamine, penicillin/streptomycin (Invitrogen, Carlsbad, CA) in 37°C, 5% CO₂ incubator.

25 *Virus generation.* vSC20, a *vgf* gene-deleted Western Reserve (WR) strain VV was used as the parental virus for homologous recombination. The plasmid pCMS1-IRES carrying two multiple cloning sites separated with an IRES sequence from pLVX-IRES-ZsGreen was constructed by us from the shuttle plasmid pSEM-1³². pCMS1-IRES was then inserted with fragments containing flexible linker or rigid linker+GPI anchor
30 sequence amplified from human CD16b by PCR, resulting plasmids pCMS1-IRES-FG or pCMS1-IRES-RG, respectively. Murine *IL-2* cDNA was inserted into pCMS1-IRES, pCMS1-IRES-FG or pCMS1-IRES-RG to get shuttle plasmids pCMS1-IL-2, pCMS1-IL-2-FG or pCMS1-IL-2-RG. GPI anchor sequence in pCMS1-IL-2-FG was further replaced with murine PD-L1 transmembrane domain to get shuttle plasmid pCMS1-IL-2-

FPTM. All these shuttle vectors were used for homologous recombination of murine *IL-2* variants into the *tk* locus of vaccinia viral genome. The primers for plasmid cloning based on PCR were listed in Table 2.

Table 2. Primers for plasmid cloning based on PCR

primer	PCR template	Resulted plasmid
p1:5'gcggtcgacatatggcgccatgcattataaggcgcgccgcccctctccctccc3' (SEQ ID NO: 19) p2:5'ggccgttaacttaagagctcatttaaatcctgcaggcgccgcattatcatcgtg3' (SEQ ID NO: 20)	pLVX-IRES-ZsGreen	pCMS1-IRES
p3:5'ggccggccggccggtggcggtgggagcggtggtgggggtccggaggcgagg3' (SEQ ID NO: 21) p4:5'ggttcggaggcgagggtcggtgtcaaccatctcatcttc3' (SEQ ID NO: 22) p5:5'gcggttaactcaaatgtttgtcttcacagag3' (SEQ ID NO: 23)	Human CD16b cDNA	pCMS1-IRES-FGPI
p6:5'ggccggccggccgctgaagctgccgcaaaagaggccgctgcgaaggaggccgcgctaag3' (SEQ ID NO: 24) p7:5'gaggccgcggttaaggaggcggcagctaaagctgcagccgtgtcaaccatctcatcttc3' (SEQ ID NO: 25) p5:5'gcggttaactcaaatgtttgtcttcacagag3' (SEQ ID NO: 26)	Human CD16b cDNA	pCMS1-IRES-RGPI
p8:5'ggcggtcgacatgtacagcatgcagctcg3' (SEQ ID NO: 27) p9:5'ccgcgccgcgccctattgagggtgtgtgag3' (SEQ ID NO: 28)	Murine IL-2 cDNA	pCMS1-IL-2-IRES
p8:5'ggcggtcgacatgtacagcatgcagctcg3' (SEQ ID NO: 29) p10:5'ccgcgccgccccttgagggtgtgtgag3' (SEQ ID NO: 30)	Murine IL-2 cDNA	pCMS1-IL-2-FG
p8:5'ggcggtcgacatgtacagcatgcagctcg3' (SEQ ID NO: 31) p10:5'ccgcgccgccccttgagggtgtgtgag3' (SEQ ID NO: 32)	Murine IL-2 cDNA	pCMS1-IL-2-RG
p3:5'ggccggccggccggtggcggtgggagcggtggtgggggtccggaggcgagg3' (SEQ ID NO: 33) p11:5'ccggaggcggtgggtcgactgggtgcttctgggatc3' (SEQ ID NO: 34) p12:5'gcggttaactacccaagaagaggaggaccgtggacact	Murine PD-L1 cDNA	pCMS1-IL-2-FPTM

acaatgaggaacaacaggatg3' (SEQ ID NO: 35)		
---	--	--

To make the new virus vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG and vvDD-IL-2-FPTM, CV-1 cells were infected with vSC20 at multiplicity of infection (MOI) of 0.1 and then transfected with the shuttle plasmids, resulting in viral seeds. Selection of the new recombinant viruses was based on expression of yellow fluorescent protein in CV1 cells 24 h post seed virus infection. vvDD-YFP, or vvDD in short, a double viral gene-deleted (*tk*- and *vgf*-) VV carrying *yfp* cDNA at the *tk* locus, is the control virus for this work.

Viral replication assays in vitro. Tumor cells were seeded at 1.0×10^5 per well in six-well plates and infected with indicated viruses next day at MOIs of 0.1, 1.0, or 10 in 1 ml medium containing 2% fetal bovine serum for 2 hours. Following infection, cells were added 3 mL medium containing 10% fetal bovine serum and cultured until harvesting at 24, 48, and 72 hours post viral infection. The cell pellet was homogenized using a FastPrep Cell Disrupter (Model FP120; Qbiogene, Carlsbad, CA) to release virions, and the resulting cell lysates were titrated on CV-1 cells to determine viral load by plaque assay.

MTS cytotoxicity assay in vitro. Tumor cells were plated at 1.0×10^4 cells per well in 96-well plates and infected with indicated viruses next day at MOIs of 0.05, 0.1, 0.5, 1.0, and 5.0. Cell viability was determined at 48 and 72 hours after infection, by CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay, or MTS assay (Promega, Madison, MI).

Viral delivered IL-2 expression in vitro. MC38-luc (3×10^5), B16 (2×10^5) or AB12-luc (3×10^5) cells were seeded in 24-well plates overnight and infected with vvDD, vvDD-IL-2, vvDD-IL-2-FG, vvDD-IL-2-RG or vvDD-IL-2-FPTM at MOI of 1 in 0.15 mL 2% FBS-containing-DMEM for 2 h. Cells were added 0.35 mL 10% FBS-containing-DMEM and cultured until harvesting at 24 h post viral infection. The culture supernatants were harvested for measuring IL-2 by ELISA (BD Bioscience, San Jose, CA) and the cell pellets were applied either to measure membrane-associated IL-2 by flow cytometry, or to extract RNA to measure IL-2 expression by RT-qPCR.

Rodent Tumor models. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc, 3.5×10^6 ID8-luc cancer cells or BALB/c mice were intraperitoneally inoculated with 4×10^5 AB12-luc, respectively, and divided into required groups 5 days or

9 days post tumor cell inoculation according to tumor size based on live animal IVIS imaging, performed using a Xenogen IVIS 200 Optical In Vivo Imaging System (Caliper Life Sciences, Hopkinton, MA). Grouped mice were intraperitoneally injected with indicated viruses, antibodies, the combinations or PBS, respectively. In some experiments, α -CD8 Ab at 250 μ g/injection (clone 53-6.7; Bio X Cell), α -CD4 Ab (clone GK1.5, Bio X Cell; 150 μ g/injection), α -NK1.1 (clone PK136, Bio X Cell; 300 μ g/injection) or α -IFN- γ Ab (clone XMG1.2, Bio X Cell; 200 μ g/injection) were intraperitoneally injected into mice to deplete CD8⁺ T cells, CD4⁺ T cells, NK1.1⁺ cells or neutralize circulating IFN- γ . In some experiments, mice were sacrificed to harvest tumor tissues and spleens at indicated time points.

MC38-luc-tumor-bearing B6 mice treated with indicated vaccinia viruses, which survived more than 60 days, were subcutaneously rechallenged with 5×10^5 MC38-luc cells per mouse. And naïve B6 mice received same dose tumor challenge as a control. The primary tumor size was measured using an electric caliper in two perpendicular diameters.

Assessment of treatment-related toxicity. Virus-treated mice were sacrificed 4 to 5 days post treatments for collection of blood, lungs, kidneys and spleens. Blood samples were kept for 2 hours at room temperature and separated sera by centrifugation for measuring IL-2 and TNF- α using commercialized kits (BD Biosciences and BioLegend, respectively), according to the vendors' instructions. Water content was used to monitor tissue edema. Briefly, wet tissue was weighed, and dehydrated overnight at 90°C in chemical hood. The weight difference between wet tissues and dry tissues was calculated.

Flow cytometry. Collected tumor tissues were weighed and incubated in RPMI 1640 medium containing 2% FBS, 1 mg/ml collagenase, 0.1 mg hyaluronidase, and 200U DNase I (All enzymes were from Sigma, St. Louis, MO) at 37°C for 1-2 h to make single cells. *In vitro* virus-infected cells or single cells from tumor tissues were blocked with α -CD16/32 Ab (clone 93) and then stained with antibodies against mouse CD45 (APC or PerCP-Cy5.5, clone: 30-F11), CD11b (PE, clone: M1/70), Ly6G (APC, clone: 1A8), Ly6C (clone: HK1.4), F4/80 (FITC, clone: BM8, e-Bioscience), CD4 (APC or FITC, clone: RM4-5, BD Biosciences), Foxp3 (PE, clone: FJK-16s, e-Bioscience), CD8 (APC or PE, clone: 53-6.7), CD44 (FITC, clone: IM7), PD-1 (PE, clone: J43, e-Bioscience), IFN- γ (APC, clone: XMG1.2, e-Bioscience), CD3 (FITC, clone: 17A2, eBioscience),

NK1.1 (PE, clone: PK136), PD-L1 (APC, clone: 10F.9G2), IL-2 (APC-SA+Biotin-IL-2, clone: JES6-5H4). All antibodies without source mentioned were purchased from BioLegend. Samples were collected on BD Accuri C6 cytometer, and data were analyzed using BD Accuri C6 cytometer software.

5 *RT-qPCR.* Total RNA was extracted from virus-infected cells or tumor tissues using the RNeasy Kit (Qiagen, Valencia, CA). One microgram of RNA was used for cDNA synthesis, and 25 to 50 ng of subsequent cDNA was used to conduct mRNA expression analysis by TaqMan analysis on the StepOnePlus system (Life Technologies, Grand Island, NY). All the primers for the analysis were purchased from Thermo Fisher Scientific (Waltham, MA). The gene expression was normalized to a house-keeping gene HPRT1 and expressed as fold increase ($2^{-\Delta CT}$), where $\Delta CT = CT_{(Target\ gene)} - CT_{(HPRT1)}$.

10 *Statistics.* Statistical analyses were performed using Student's t test (GraphPad Prism version 7). Animal survival is presented using Kaplan-Meier survival curves and was statistically analyzed using log rank test (GraphPad Prism version 7). Value of $P < 0.05$ is considered to be statistically significant, and all P values were two sided. In the figures, the standard symbols were used: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; and **** $P < 0.0001$.

8.3 Results

Viruses vvDD-IL-2, vvDD-IL-2-FPTM, vvDD-IL-2-FG and vvDD-IL-2-RG were generated based on vvDD (FIGURE 9). In brief, vvDD-IL-2 produced secreted murine IL-2 and vvDD-IL-2-FPTM, vvDD-IL-2-FG and vvDD-IL-2-RG displayed murine IL-2 on cell membrane post infection. vvDD-IL-2-FPTM produced IL-2 fused with murine PD-L1 transmembrane domain and a flexible linker (G_4S)₃ in between. vvDD-IL-2-FG and vvDD-IL-2-RG produced IL-2 fused with glycoinositol phospholipid (GPI) anchor sequence of human CD16b, and a flexible linker (G_4S)₃ and a rigid linker (A(EA₃K)₄AAA) in between, respectively. These four viruses have similar capacity of replication and cytotoxicity in tumor cells, compared with parental virus vvDD (FIGURE 10). vvDD-IL-2 produced significantly more IL-2 in supernatant than others, but not membrane associated IL-2. vvDD-IL-2-FPTM, vvDD-IL-2-FG and vvDD-IL-2-RG produced few IL-2 in supernatant, but significantly more membrane-associated IL-2 than VVDD-IL-2. The amount of membrane associated IL-2 in vvDD-IL-2-RG was more than vvDD-IL-2-FG and the amount of membrane associated IL-2 in vvDD-IL-2-FG was more than vvDD-IL-2-FPTM (FIGURE 11A).

Next, the mRNA levels of IL-2 and viral marker gene A34R were determined in tumor cell post virus infection *in vitro*. The data showed that viral gene A34R mRNA were similar, but IL-2 mRNA pattern was similar to the pattern of the membrane associated IL-2 amount described above. Without being bound to a particular theory, this shows that the precise component of chimeric proteins can impact the mRNA stability and further impact the amount of IL-2 displaying on cell membrane (FIGURE 12).

To evaluate the antitumor efficacy of the four viruses, each virus was injected intraperitoneally at the dose of 2×10^8 PFU/mouse to treat B6 mice received murine colon cancer cell MC38-luc inoculation 5 days ago (early-stage tumor model). The survival results showed that vvDD-IL-2, vvDD-IL-2-FG and vvDD-IL-2-RG, but not vvDD-IL-2-FPTM, elicited more potent antitumor effects compared with PBS or vvDD (FIGURE 11B). Without being bound to a particular theory, this can be explained by the low amount of IL-2 displayed on cell membrane post vvDD-IL-2-FPTM infection (FIGURE 11A and FIGURE 12). The mice treated with vvDD-IL-2 survived longer than those treated with vvDD-IL-2-FG, but not than those treated with vvDD-IL-2-RG (FIGURE 11B).

All the mice that survived the vvDD-IL-2, vvDD-IL-2-FG and vvDD-IL-2-RG treatment rejected a subcutaneous tumor rechallenge, which showed that a systemic antitumor response was elicited (FIGURE 13). A few mice died within one week post vvDD-IL-2 treatment (FIGURE 11B). Without being bound to a particular theory, this could be a sign of IL-2-induced toxicity. To investigate if secreted IL-2 produced by vvDD-IL-2 treatment can induce systemic toxicity to some degree and be more toxic for mice with heavy tumor burden, the safety and antitumor efficacy of the viruses with the same virus dosage was assessed by switching from an 5-day-tumor-bearing mouse model (early-stage tumor model) to a 9-day-tumor-bearing mouse model (late-stage tumor model), a more immunosuppressive tumor model, in which the mouse has a higher tumor burden, more immunosuppressive CD4⁺Foxp3⁺, CD4⁺PD-1⁺ and CD8⁺PD-1⁺ T cells, G-MDSC and PD-L1⁺ cells, less NK cells and higher PD-1, PD-L1, TGF- β and VEGF expression in the tumor microenvironment, compared with the early-stage tumor model (FIGURES 14 and 15). The late-stage tumor mice also have increased severe edema in the livers and kidneys (FIGURE 15), compared with the early-stage tumor model. The therapeutic results from the late-stage tumor model showed that the vvDD-IL-2 treatment led to a high mortality within one-week post treatment, whereas treatment with the other viruses were safe. The vvDD-IL-2-FG and vvDD-IL-2-RG treatments significantly

extended the animal survival, compared with the vvDD treatment, however, the vvDD-IL-2-RG treatment elicited a significantly better survival (FIGURE 11C and FIGURE 16A).

To further investigate the toxicity induced by the viruses, IL-2 serum levels were measured and it was found that they were 100 times higher in the serum of mice treated with vvDD-IL-2, compared to the serum of mice treated with the other viruses and reached about 24950 pg/mL (FIGURE 16B). Low levels of IL-2 were also detected in the serum of mice treated with vvDD-IL-2-FG and vvDD-IL-2-RG. Without being bound to any particular theory, this can be explained due to the more loose association of the GPI-anchored proteins with the cell membrane, compared to transmembrane proteins and could be spontaneously released from the cell membrane due to shedding or proteolytic cleavage and also because free GPI-anchored proteins could also transfer to cell membrane via a process termed “cell surface painting”¹⁸.

To examine if IL-2 can induce an increase in the TNF- α serum levels¹⁹, TNF- α serum levels were measured after vvDD-IL-2 treatment and it was found that vvDD-IL-2 treatment induced a significant increased in the TNF- α serum levels (FIGURE 16C). Mice were also assessed for tissue edema, a hallmark for measuring IL-2 induced vascular leak syndrome²⁰. Only vvDD-IL-2 treatment induced substantial more pulmonary and hepatic edema, as evidenced by the water content increase in lungs and livers (FIGURES 16D-16E). Tissue edema was also found. Additionally, increased IL-2 serum levels were found in vvDD-IL-2-treated mice, even on the early-stage tumor model (FIGURES 17A-17D). Taken together, these data showed that vvDD-IL-2-FG and vvDD-IL-2-RG treatments were safer than vvDD-IL-2.

Treatments with vvDD-IL-2-FG and vvDD-IL-2-RG have similar therapeutic efficacy in early-stage tumor model. However, only vvDD-IL-2-RG treatment resulted in a substantial better survival in late-stage tumor model, even though both treatments had a similar safety profile. To explore the reason behind this result, the immune cell profile in tumor microenvironment and spleens was investigated using a late-stage tumor model. The percentages of activated CD4⁺Foxp3⁻ and CD8⁺IFN- γ ⁺ T cells from tumors that received vvDD-IL-2-RG treatment were higher, compared to tumors that received other virus treatment (FIGURES 18A and 18B). To examine if memory CD8⁺ T cells and NK cell can readily respond to IL-2²¹, memory CD8⁺CD44^{hi} T cells and CD3⁻NK1.1⁺ cells were examined. The percentages of both types of cells from tumors post virus treatment

had the same pattern with the activated T cells described above. Similar results were even observed in spleen (FIGURE 18C and FIGURE 19A-19C).

Further, the presence of CD4⁺Foxp3⁺ T cells in tumors that received virus treatment were examined. The percentages of CD4⁺ T regulatory cells in tumors were similar to the ones described above (FIGURE 18D). Thus, the CD8⁺/Treg ratio in tumors that received vvDD-IL-2-RG treatment was significantly higher, since CD8⁺ T cells were elevated in tumor post vvDD-IL-2-RG treatment compared to tumors that received other virus treatment (FIGURE 18E and FIGURE 19D).

Next, the expression of protumoral and antitumoral factors was examined in tumors collected from the late-stage tumor model post virus treatment. There was an increased expression of IFN- γ , Granzyme B, perforin, and decreased expression of TGF- β and angiogenesis markers CD105 and VEGF in tumors that received vvDD-IL-2-RG treatment, compared to tumors that received the other virus treatments (FIGURES 18F-18K). Expression of IL-10 was also found to be significantly elevated in tumors received VVDD-IL-2-RG treatment (FIGURE 18L). Without being bound to a particular theory, although IL-10 can function as both immune stimulation and immune suppression in cancer, here IL-10 can have an inhibitory effect on the expression TNF- α , which was elevated by IL-2 and recently suggested as a tumor growth factor for minimal residual tumor, thereby making VVDD-IL-2-RG treatment safer and more effective (FIGURE 16C)^{19,22-24}.

To examine if the antitumor effect elicited by vvDD-IL-2-RG treatment was IFN- γ and CD8⁺ T cell dependent or CD4⁺ T cell dependent, IFN- γ , CD4⁺ and CD8⁺ T cells and NK1.1⁺ cells were depleted by antibodies post vvDD-IL-2-RG treatment. The results demonstrated that the antitumor effect elicited by vvDD-IL-2-RG treatment was IFN- γ and CD8⁺ T cell dependent, and not CD4⁺ T cell dependent (FIGURE 18M). The results also demonstrated that the NK cell depletion led to a significantly better survival compared to the vvDD-IL-2-RG treatment alone. Without being bound to a particular theory, the reason could be that the NK cells could impede virotherapy via the natural cytotoxicity receptor NKP46. The expression of NKP46 was significantly increased by the vvDD-IL-2-RG treatment, thus, NK cell depletion could have removed this impediment (FIGURE 20)²⁵.

Collectively, these data demonstrated that vvDD-IL-2-RG treatment turned the immune status in tumor-bearing mice from immune-suppressive to immune-favorable, which finally led to a better survival.

Combination of oncolytic vaccinia virus with an anti-PD-L1 antibody was previously suggested to work synergistically to enhance therapeutic efficacy on early-stage tumor model²⁶. However, the combination of vvDD with the anti-PD-L1 antibody did not work in the late-stage tumor model (FIGURE 21). Both vvDD-IL-2-FG and vvDD-IL-2-RG treatments elicited antitumor effects on the late-stage tumor model, and induced high PD-1, PD-L1 and CTLA-4 expression in tumors (FIGURE 11C, FIGURES 22A-22C, and FIGURES 23A-23C). Therefore, combination of vvDD-IL-2-FG and vvDD-IL-2-RG and anti-PD-1/PD-L1 or anti-CTLA-4 antibodies was tested to investigate whether the combination could treat 9-day-tumour-bearing mice. The results showed that vvDD-IL-2-RG combined with an anti-PD-1/PD-L1 antibody, but not with an anti-CTLA-4 antibody, cured tumor-bearing mice (FIGURE 22D). Without being bound to a particular theory, this could be attributed to the different mechanisms for anti-CTLA-4 and anti-PD-1/PD-L1 checkpoint blockade. Anti-CTLA-4 antibodies primarily affect CD4⁺ T cells at prime phase, while anti-PD-1/PD-L1 antibodies predominantly act on exhausted T cells within the tumor, which could be important for overcoming the more immunosuppressive microenvironment in late-stage large solid tumors. The combination of VVDD-IL-2-FG with anti-PD-1/PD-L1 antibody did not improve the survival. Without being bound to a particular theory, this suggests that changes in immune status in tumor-bearing mice, especially in late-stage-tumor-bearing mice, was essential for the effectiveness of the monotherapy and the combination therapy. This could be evidenced by several recent reports showing the effectiveness of oncolytic viruses combined with immune checkpoint blockade in preclinical models and clinical trials (FIGURE 22D and FIGURE 24)²⁷⁻³⁰.

In summary, the present Example demonstrated that vvDD-IL-2-RG treatment could effectively elicit antitumor immune status change in late-stage-tumor-bearing mice with significantly reduced systemic toxicity which was induced by IL-2 application, and finally led to a much better survival. The combination of vvDD-IL-2-RG with anti-PD-1 and PD-L1 antibodies can cure mice with late-stage-tumor. Thus, the present Example showed that vvDD-IL-2-RG treatment can be a new form of IL-2 immunotherapy that can be translatable to the clinic for cancers and immunosuppressive cancers.

8.4 References

1. Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol* 12, 180-190, doi:10.1038/nri3156 (2012).
- 5 2. Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. *Immunity* 38, 13-25, doi:10.1016/j.immuni.2013.01.004 (2013).
3. Lotze, M. T. et al. *In vivo* administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells *in vivo* with recombinant IL 2. *J Immunol* 135, 2865-2875 (1985).
- 10 4. Yang, J. C. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. *J Clin Oncol* 21, 3127-3132, doi:10.1200/JCO.2003.02.122 (2003).
5. Hu, P., Mizokami, M., Ruoff, G., Khawli, L. A. & Epstein, A. L.
- 15 Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. *Blood* 101, 4853-4861, doi:10.1182/blood-2002-10-3089 (2003).
6. Melder, R. J. et al. Pharmacokinetics and *in vitro* and *in vivo* anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. *Cancer Immunol Immunother* 54, 535-547, doi:10.1007/s00262-004-0624-7 (2005).
- 20 7. Puskas, J. et al. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. *Immunology* 133, 206-220, doi:10.1111/j.1365-2567.2011.03428.x (2011).
8. Vazquez-Lombardi, R. et al. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells. *Nat Commun* 8, 15373, doi:10.1038/ncomms15373 (2017).
- 25 9. Lazear, E. et al. Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy. *Oncoimmunology* 6, e1265721, doi:10.1080/2162402X.2016.1265721 (2017).
10. Boyman, O., Surh, C. D. & Sprent, J. Potential use of IL-2/anti-IL-2
- 30 antibody immune complexes for the treatment of cancer and autoimmune disease. *Expert Opin Biol Ther* 6, 1323-1331, doi:10.1517/14712598.6.12.1323 (2006).
11. Letourneau, S. et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. *Proc Natl Acad Sci U S A* 107, 2171-2176, doi:10.1073/pnas.0909384107 (2010).

12. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. *Nature* 484, 529-533, doi:10.1038/nature10975 (2012).
13. Katre, N. V., Knauf, M. J. & Laird, W. J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine
5 Meth A sarcoma model. *Proc Natl Acad Sci U S A* 84, 1487-1491 (1987).
14. Qin, H. et al. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. *Mol Ther* 4, 551-558, doi:10.1006/mthe.2001.0493 (2001).
15. Zeh, H. J. et al. First-in-human study of Western Reserve Strain oncolytic
10 vaccinia virus: safety, systemic spread and anti-tumor activity. *Mol Ther* (In press) (2014).
16. Pan, W. Y. et al. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. *Mol Ther* 20, 927-937, doi:10.1038/mt.2012.10 (2012).
17. Ji, J. et al. Glycoinositol phospholipid-anchored interleukin 2 but not
15 secreted interleukin 2 inhibits melanoma tumor growth in mice. *Mol Cancer Ther* 1, 1019-1024 (2002).
18. Paulick, M. G. & Bertozzi, C. R. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. *Biochemistry* 47, 6991-7000, doi:10.1021/bi8006324 (2008).
19. Baluna, R. & Vitetta, E. S. Vascular leak syndrome: a side effect of
20 immunotherapy. *Immunopharmacology* 37, 117-132 (1997).
20. Rosenstein, M., Ettinghausen, S. E. & Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. *J Immunol* 137, 1735-1742 (1986).
21. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. *Science* 311, 1924-1927, doi:10.1126/science.1122927 (2006).
22. Dennis, K. L., Blatner, N. R., Gounari, F. & Khazaie, K. Current status of interleukin-10 and regulatory T-cells in cancer. *Curr Opin Oncol* 25, 637-645, doi:10.1097/CCO.0000000000000006 (2013).
23. Lentsch, A. B. et al. Interleukin-10 inhibits interleukin-2-induced tumor necrosis factor production but does not reduce toxicity in C3H/HeN mice. *J Leukoc Biol* 60, 51-57 (1996).

24. Kottke, T. et al. Subversion of NK-cell and TNFalpha Immune Surveillance Drives Tumor Recurrence. *Cancer Immunol Res* 5, 1029-1045, doi:10.1158/2326-6066.CIR-17-0175 (2017).
25. Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. *Nat Med* 18, 1827-1834, doi:10.1038/nm.3013 (2012).
26. Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S. & Bartlett, D. L. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. *Nat Commun* 8, 14754, doi:10.1038/ncomms14754 (2017).
27. Saha, D., Martuza, R. L. & Rabkin, S. D. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. *Cancer Cell* 32, 253-267 e255, doi:10.1016/j.ccell.2017.07.006 (2017).
28. Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. *Sci Transl Med* 10, doi:10.1126/scitranslmed.aam7577 (2018).
29. Bourgeois-Daigneault, M. C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. *Sci Transl Med* 10, doi:10.1126/scitranslmed.aao1641 (2018).
30. Ribas, A. et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell* 170, 1109-1119 e1110, doi:10.1016/j.cell.2017.08.027 (2017).
31. Liu, Z. et al. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. *OncoImmunology* 5 (2016).
32. Rintoul, J. L. et al. A selectable and excisable marker system for the rapid creation of recombinant poxviruses. *PloS one* 6, e24643, doi:10.1371/journal.pone.0024643 (2011).

9. EXAMPLE 4: ADOPTIVE TRANSFER OF TUMOR-SPECIFIC
TUMOR-INFILTRATED T CELLS LED TO SIGNIFICANT THERAPEUTIC
EFFECTS IN SYNGENEIC C57BL/6 MICE BEARING PERITONEAL MC38
TUMOR.

5 9.1 Introduction

Immunotherapy is rapidly evolving and fighting cancer by re-activating the patient immune system presents an attractive therapeutic strategy for gastrointestinal cancer besides standard treatments as surgery, chemotherapy and radiotherapy. Gastrointestinal cancer including colorectal, gastric, liver and biliopancreatic cancer belong to the ten most frequent malignancies worldwide (1). Immune infiltration impacts tumor progression and patient survival and that a strong lymphocyte infiltration has been reported to be associated with an antitumor response and improved clinical outcome in several GI adenocarcinomas (2-9). Different immunotherapeutic strategies as cancer vaccines, adoptive T cell transfer of autologous T cells or checkpoint blockade have been developed but are still not available for a wide range of GI tumors due to tumor heterogeneity and poor immune infiltration. Tumor cells develop immune escape mechanism modulating the immune system to avoid detection by effector cells. This includes cell surface expression of immune system checkpoint ligands such as programmed death ligand 1(PD-L1) (10,11), secretion of soluble immunosuppressive factors such as transforming growth factor beta (TGF- β), vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), galectin-1, indoleamine 2,3-dehydrogenase (12-14), and down-regulation of major histocompatibility complex (MHC) class I expression; overexpression of receptors such as C-X-C chemokine receptor type 4 (CXCR4), basic fibroblast growth factor and epidermal growth factor (15,16).

25 The immunosuppressive tumor microenvironment presents optimal conditions for the recruitment of immunosuppressive macrophages, MDSCs and Tregs interfering with an efficient anti-tumor T cell response. Inhibitory checkpoint molecules as CTL-4, PD-1, TIM3, LAG3, upregulated in chronically stimulated T cells, promoting even further T cell anergy. A strategy to reverse the immunosuppressive tumor microenvironment (TME) and break immune tolerance is presented by oncolytic virotherapy. After selectively
30 infecting and replicating in cancer cells and associated endothelial cells they kill these cells in cancerous tissue while leaving unaffected, healthy tissue unharmed (17,18). Immunogenic cell death (ICD) of stromal cells and cancer cells induced by OV exposes a natural repertoire of tumor-associated antigens (TAAs) in conjunction with danger signals

(damage associated molecular pattern (DAMPs)) and OV-derived pathogen-associated molecular pattern (PAMP) molecules and inflammatory cytokines to elicit anti-tumor immunity (19-21). In a randomized phase II clinical trial in patients with advanced hepatocellular carcinoma, an oncolytic vaccinia virus armed with GM-CSF (Pexa-Vec) was associated with a 15% objective response rate (22). In a phase I clinical trial, an oncolytic vaccinia virus (Western Reserve Strain) vvDD was shown to be tumor selective and to promote anti-tumor response (23,24). To improve the immune response various oncolytic VV were engineered to express tumor antigens, T-cell co-stimulatory molecules and inflammatory cytokines (25). Their efficacy and safety have been demonstrated in preclinical studies (26-30). The present Example showed for the first time that oncolytic vaccinia virus-induced tumor infiltrating T cells (OV-induced T cells) (also referred to herein as “tumor-infiltrated T cells” or “TILs”) can be used for *ex vivo* expansion and adoptive T cell transfer as new immunotherapeutic approach.

9.2 Methods

Mice and cell lines. Female C57BL/6 mice were obtained from The Jackson Laboratory (Bar, Harbor, ME, USA) and housed in specific pathogen-free conditions in the University of Pittsburgh animal facility. All animal studies were approved by the Institutional Animal Care and Use Committee of the University. Murine colon cancer cell lines MC38 and B16 were obtained from ATCC. Mouse colon cancer MC38-luc was generated as described previously. All cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1x penicillin/streptomycin solution (Invitrogen, Carlsbad, CA) in 37°C, 5% CO₂ incubator.

Viruses. Recombinant vaccinia virus (Western Reserve strain) vvDD, vvDD-CCL5 (31) and vvDD-CXC11 (32) were previously described. In the presently disclosed subject matter newly developed vvDD-IL-15 and vvDD-IL-2 are also provided. Virus has been purified in HeLa cells. Virus titer has been defined in CV-1 cells using plaque assay. For intratumoral virus application 1e8 pfu per mouse have been used.

Rodent Tumor models. For subcutaneous (s.c.) tumor model, B6 mice were subcutaneously inoculated with 5x10⁵ MC38 cancer cells. vvDD-IL-2, vvDD-IL-15, vvDD-CXC11, vvDD-CCL5, vvDD or PBS was intratumorally injected at 1e8 pfu/tumor when the s.c. tumor area reached 5x5 mm². In some experiments IL-2 was administered intratumoral with 1x10⁶ IU per tumor (Prometheus, San Diego, CA). The primary tumor size was measured using an electric caliper in two perpendicular diameters followed by

every other day measurement. 10 days post virus treatment tumor tissue or spleen has been collected and proceed to single cell suspension for T cell separation and further analysis. For peritoneal (i.p.) tumor models, B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cells and randomized according to tumor size based on live animal
 5 IVIS imaging 7 days post tumor cell injection using a Xenogen IVIS 200 Optival In Vivo Imaging System (Caliber Life Sciences, Hoptikon, MA).

Generation of tumor reactive T-cells for adoptive transfer. B6 mice were s.c. inoculated with 5×10^5 MC38 cancer cells. When the tumor area reached $5 \times 5 \text{ mm}^2$ vvDD-IL-2 (1×10^8 pfu per tumor) was intratumorally injected. 10 days later tumors have been
 10 collected and were incubated at 37°C in digestion buffer (Miltenyl Biotec, San Diego, CA) before being mashed over a $100 \mu\text{M}$ tissue strainer. Lysis of red blood cell was performed using ACK Lysing buffer (Thermo Fisher Scientific, Waltham, MA). For Leukocyte separation Percoll (GE, Healthcare Life Science, Marlborough, MA) gradient centrifuge was used adapted from the protocol by Liu et al (Liu, Y., Chen, K., Wang, C.,
 15 Gong, W., Yoshimura, T., Wang, J. M. and Liu, M. (2013). Isolation of Mouse Tumor-Infiltrating Leukocytes by Percoll Gradient Centrifugation. *Bio-protocol* 3(17): e892. DOI: 10.21769/BioProtoc.892). Leucocytes collected at the interface between 40% and 80% discontinuous Percoll gradient followed by magnetic separation (CD90.2 beads, Miltenyl Biotec, San Diego, CA). T cells have been cultured in 24-well plates in a
 20 concentration with 1×10^6 per well in RPMI complete media with 30 IU/ml IL-2 (Miltenyl Biotec, San Diego, CA) and 5 ng/ml IL-7 (Biolegend, San Diego, CA) over 4 days. As control T cells, spleens from non-tumor bearing untreated mouse have been harvested and proceed to single cell suspension followed by magnetic separation (CD90.2 beads). The naïve T cells have been cultured under the same conditions as the virus induced T cells.
 25 Prior to adoptive T cell transfer, T cells have been analyzed for tumor specificity in a co-culture assay. T cells (2×10^4 per well) were either left unstimulated (medium) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well, 96-well plate) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse in duplicate for 24 h.
 30 The plate setup has been used for IFN- γ ELISPOT or Flow cytometry analysis as described above.

Adoptive cell transfer and cytokine administration. B6 mice were intraperitoneally inoculated with 5×10^5 MC38-luc cancer cells and divided into required groups according to tumor growth condition based on live animal IVIS imaging 7 days

post tumor cell injection. Grouped mouse received 1×10^6 vvDD-IL-2 induced T cells, naïve T cells or PBS. All treatment mouse received 5 Gy of sublethal irradiation to mimic lymphodepletion according to clinical protocols prior to cell transfer and exogenous cytokine support of IL-2 (100,000 IU/mouse i.p. for 3 days post transfer every 12h) (Prometheus, San Diego, CA).

Flow cytometry. Post 24 h co-culture assay was performed as described above. T cells were stained using Zombi aqua (Biolegend, San Diego, CA) followed by staining with antibodies against mouse CD3, CD8, CD4, 4-1BB (Biolegend, San Diego, CA). Samples were collected by BD Bioscience LSR II Fortessa. Data were analyzed by BD FACS Diva software and FlowJo software (Tree Star Inc., Ashland, OR).

IFN- γ ELISPOT. Collected tumor tissues were incubated at 37°C in digestion buffer (Miltenyl Biotec, San Diego, CA) before being mashed over a 100 μ M tissue strainer. Lysis of red blood cell was performed using ACK Lysing buffer (Thermo Fisher Scientific, Waltham, MA) and single cell suspension was proceeded by straining cell suspension over 40 μ M filter. Isolation of CD8⁺ T cells was performed using negative α -mouse CD8 microbeads isolation protocol (Miltenl Biotec, San Diego, CA). 96 well Plates (MAHAS4510, Millipore, Burlington, MA) were coated with anti-mouse IFN- γ mAb 15mg/ml (clone AN18, Mabtech Inc., Cincinnati, OH). T cells (2×10^4 per well) were either left unstimulated (medium) or challenged with γ -irradiated MC38 tumor cells (2×10^4 per well, 96-well plate) or irrelevant target cells as γ -irradiated B16 tumor cells (2×10^4 per well) or naïve splenocytes (2×10^4 per well) from non-tumor-bearing B6 mouse in duplicate for 24 h.

After appropriate washes, biotylated secondary antibody (clone R4-6A2-biotin, Mabtech, Inc) was added and incubated at room temperature for 2 h. Spot development followed using Vectastain Elite ABC and AEC Peroxidase substrate (SK-4200) kits (Vector Laboratories, Inc. Burlingame, CA). Number of IFN- γ spots were analyzed by ImmunoSpotTM (Cellular Technology, Ltd., Shaker Heights, OH).

Long-term survival of mice. The health and survival of treated mice was closely monitored. All mice bearing subcutaneous or peritoneal tumors were monitored via caliper measurements for changes in tumor size or abdominal girth. Mice died naturally due to the disease or sacrificed when their subcutaneous tumor size exceeded 20 mm in diameter or when abdominal girth exceeded 1.5 $\times$ the original measurement.

Statistics. Statistical analyses were performed using Student's *t* test (GraphPad Prism version 5). Animal survival is presented using Kaplan-Meier survival curves and

was statistically analyzed using log rank test (GraphPad Prism version 5). Value of $p < 0.05$ is considered to be statistically significant, and all p values were two sided. In the figures, the standard symbols were used: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; and NS: not significant.

5 9.3 Results

vvDD-IL-2 is a potent modulator of the TME attracting high numbers of tumor reactive T cells.

To test if the different vaccinia virus constructs enhance the anti-tumor immune response and attract T cells into the TME, the T cell immune response in the TME of MC38 s.c. tumor bearing mouse was tested 10 days post intratumoral virus treatment with vvDD, vvDD-CXC11, vvDD-CCL5, vvDD-IL-15, vvDD-IL-2 or PBS. CD8⁺ T cells from virus-treated tumors were analyzed for IFN- γ response by ELISPOT. Compared to PBS control, all virus-treated tumors presented a significant increase in reactive CD8⁺ T cells when tested against γ -irradiated MC38 tumor cells. vvDD-IL-2 treated tumors presented the highest level of reactive CD8⁺ T cells compared to vvDD or vvDD-IL-15 treated tumors (FIGURE 25A).

To investigate whether virus-induced CD8⁺ T cells are tumor specific, the IFN- γ response of CD8⁺ T cells from vvDD-IL-2, vvDD or PBS treated tumors was measured post co-culture with irrelevant target cells, *e.g.*, γ -irradiated B16 tumor cells, naïve splenocytes from non-tumor-bearing B6 mouse and γ -irradiated MC38 tumor cells. Virus-treated tumors presented a significant increase in MC38-reactive CD8⁺ T cells compared to PBS control. vvDD-IL-2 induced CD8⁺ T cells exhibited highly specific reactivity against MC38 tumor cells compared to irrelevant target cells, *e.g.*, B16 and naïve splenocytes. The vvDD induced T cells presented similar levels of MC38 reactivity compared to vvDD-IL-2, but exhibited higher background reactivity against the unspecific control cells as B16 and naïve splenocytes compared to vvDD-IL-2 (FIGURE 25B). In summary, the vvDD-IL-2 induced T cells are highly MC38 specific.

Virally expressed IL-2 promotes a strong infiltration of tumor reactive CD8⁺ T cells in the TME compared to single IL-2 treatment. To study the ability of the single IL-2 treatment to attract T cells into the TME in comparison to the IL-2-armed virus therapy, MC38 s.c. tumor bearing mouse were treated intratumorally with IL-2, vvDD-IL-2, vvDD or PBS. 10 days later, tumor infiltrating CD8⁺ T cells were analyzed for IFN- γ response

by ELISPOT. The IFN- γ response of vvDD-IL-2 induced CD8⁺ T cells was prior compared to IL-2 treatment, control virus or PBS (FIGURE 26).

vvDD-IL-2 promotes T cell infiltration in the TME of MC38 tumor bearing mouse.

To quantify the ability of vvDD-IL-2 to promote T cell infiltration in the TME, treated
5 tumors were analyzed by immunofluorescence staining for total CD3⁺ infiltrating cells
and CD3⁺CD8⁺ and CD3⁺CD4⁺ T cells (FIGURES 27 and 28). Both virus constructs
promote significant increase of total CD3⁺ cells and CD8⁺ T cell infiltration in the TME
compared to PBS control. Virus treatment presented an increase in CD4⁺ T cell
infiltration compared to PBS samples. Similar results were observed in other
10 experimental setups, when T cells were purified from tumor tissue and quantified per
gram tumor (FIGURE 28).

*vvDD-IL-2 induced tumor infiltrating T cells can be expanded and keep their
tumor specificity.* To test if vaccinia virus induced T cells can present a new strategy for
adoptive T cell transfer, an *ex vivo* culture protocol of the tumor infiltrating T cells was
15 established for T cell induction in MC38 s.c. tumor bearing mouse that were treated with
vvDD-IL-2, vvDD or PBS (FIGURE 29A). 10 days later tumors were harvested and
infiltrating CD8⁺ T cells and CD4⁺ T cells from each tumor were cultured in the
presence of IL-2 and IL-7 in RPMI complete media.

To test if the cultured T cells kept their tumor specificity, the T cells were tested
20 for their tumor recognition using a co-culture assay, including relevant target cells
(irradiated MC38 tumor cells) and irrelevant target cells as γ -irradiated B16 tumor cells or
naïve splenocytes from non-tumor-bearing B6 mouse. After 24 h, the cells were analyzed
for tumor specificity using IFN- γ ELISPOT or 4-1BB expression by flow cytometry.
According to the IFN- γ ELISPOT, T cells from vvDD-IL-2, vvDD or PBS treated tumors
25 presented tumor specific IFN- γ secretion compared to irrelevant target cells, *e.g.*, B16 or
naïve splenocytes (FIGURE 29B).

To distinguish between CD8⁺ and CD4⁺ tumor specific T cell response flow
cytometry results from each sample were summarized in FIGURE 29C. vvDD-IL-2
induced T cells presented highly tumor specific CD8⁺ and CD4⁺ T cells with less
30 unspecific reactivity against irrelevant target cells when compared to vvDD or PBS group
(FIGURE 29C). Representative flow cytometry plot of CD8⁺ 4-1BB⁺ and CD4⁺ 4-1BB⁺
T cells of one sample from each group is shown in FIGURE 30.

*vvDD-IL-2 generated tumor reactive T cells present a new strategy for adoptive T
cell transfer.* The newly developed approach of oncolytic virus induced T cells for ACT

has been tested in MC38 i.p. tumor bearing mouse. Prior to T cell transfer, treated mouse received 5 Gy of sublethal irradiation to mimic lymphodepletion similar to clinical protocols. Grouped mouse were intraperitoneally injected with vvDD-IL-2-induced T cells, naïve T cells or PBS. All treated mouse received exogenous cytokine support of IL-2. The therapeutic response was monitored by live animal bioluminescence imaging to monitor the kinetics of tumor growth over time (FIGURE 33C). Mouse that received vvDD-IL-2 induced T cells presented the strongest tumor regression compared to control mouse. In terms of animal survival, the virus-generated T cells led to the best overall survival compared to mice that received naïve T cells or only irradiation with IL-2 or PBS (FIGURE 33C). Imaging Day 17 post ACT is shown in FIGURE 34.

In summary, in the presently disclosed pre-clinical model the virus induced T cells present a therapeutic potential. To explore the tumor specificity of the transferred T cells, prior to ACT the established co-culture assay was performed (FIGURE 31). Representative flow cytometry plot of CD8⁺ 4-1BB⁺ and CD4⁺ 4-1BB⁺ T cells of one sample from each group is shown in FIGURE 32. T cells were analyzed for 4-1BB expression by flow cytometry and IFN- γ secretion by ELISPOT. Virus derived T cells presented tumor specific IFN- γ spots with nearly no reactivity against irrelevant target cells compared to naïve T cells (FIGURES 31B AND 31C). When the T cells from the same samples as used for ELISPOT were analyzed for 4-1BB expression, only the virus induced T cells presented significant tumor specific CD8⁺4-1BB⁺ and CD4⁺4-1BB⁺ expression when compared to control group.

9.4 Discussion

The present Example shows that cytokine-armed oncolytic vaccinia virus can promote intratumoral T cell infiltration and generates tumor specific T cells (OV-induced T cells) for adoptive T cell transfer.

A strong lymphocyte infiltration has been reported to be associated with an antitumor response and improved clinical outcome. But the majority of patients with gastrointestinal malignancies present pure immune cell infiltrated tumors with a highly immunosuppressive microenvironment. The application of oncolytic vaccinia virus with induction of immunogenic cell death offers an effective strategy to overcome less immunogenic tumors. Viral mediated cell death results in the release of potent danger signals and cross presentation of tumor-associated antigens, resulting in antitumor innate and adaptive immunity. In the present Example, the use of vaccinia virus induced tumor infiltrating T cells for *ex vivo* expansion and adoptive T cell transfer in a pre-clinical

murine colon cancer model was demonstrated. Intratumoral application of cytokine-armed oncolytic vaccinia virus promotes T cell infiltration into the TME. The virus induced T cells were highly tumor specific and kept their therapeutic potential when expanded *ex vivo* and transferred into tumor bearing mouse. The present Example presents a strategy to promote intratumoral T cell infiltration and to generate tumor specific T cells in the tumor microenvironment for adoptive T cell transfer.

9.4. References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29 doi 10.3322/caac.21208.
2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12(4):298-306 doi 10.1038/nrc3245.
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4 doi 10.1126/science.1129139.
4. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molitor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66 doi 10.1056/NEJMoa051424.
5. Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003;89(9):1736-42 doi 10.1038/sj.bjc.6601331.
6. Takagi S, Miyagawa S, Ichikawa E, Soeda J, Miwa S, Miyagawa Y, et al. Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma. Hum Pathol 2004;35(7):881-6.
7. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25(18):2586-93 doi 10.1200/JCO.2006.09.4565.
8. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004;28(1):e26-31.

9. Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. *Br J Cancer* 2008;99(10):1704-11 doi 10.1038/sj.bjc.6604738.
10. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al.
5 Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res* 2007;13(7):2151-7 doi 10.1158/1078-0432.CCR-06-2746.
11. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al.
10 Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. *Clin Cancer Res* 2009;15(3):971-9 doi 10.1158/1078-0432.CCR-08-1608.
12. Martínez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz-Zapater E, Munné-Collado J, Iglesias M, et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. *Cancer Res* 2014;74(13):3512-24
15 doi 10.1158/0008-5472.CAN-13-3013.
13. Kobayashi N, Kubota K, Kato S, Watanabe S, Shimamura T, Kirikoshi H, et al. FOXP3⁺ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. *Pancreatology* 2010;10(5):631-40 doi 10.1159/000308966.
14. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. *Clin Cancer Res* 2006;12(4):1144-51 doi 10.1158/1078-0432.CCR-05-1966.
15. Feig C, Jones JO, Kraman M, Wells RJ, Deonaraine A, Chan DS, et al.
25 Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci U S A* 2013;110(50):20212-7 doi 10.1073/pnas.1320318110.
16. Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. *Adv Cancer Res* 2014;124:31-82 doi 10.1016/B978-0-12-411638-2.00002-1.
30 2.00002-1.
17. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. *Nat Biotechnol* 2012;30(7):658-70 doi 10.1038/nbt.2287.

18. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. *Biochim Biophys Acta* 2008;1785(2):217-31 doi 10.1016/j.bbcan.2008.02.001.
19. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. *Immunol Rev* 2012;249(1):158-75 doi 10.1111/j.1600-065X.2012.01146.x.
20. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. *Science* 2002;296(5566):298-300 doi 10.1126/science.1068883.
21. Matzinger P. The danger model: a renewed sense of self. *Science* 2002;296(5566):301-5 doi 10.1126/science.1071059.
22. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. *Nat Med* 2013;19(3):329-36 doi 10.1038/nm.3089.
23. Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. *Mol Ther* 2015;23(1):202-14 doi 10.1038/mt.2014.194.
24. Downs-Canner S, Guo ZS, Ravindranathan R, Breitbach CJ, O'Malley ME, Jones HL, et al. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. *Mol Ther* 2016;24(8):1492-501 doi 10.1038/mt.2016.101.
25. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov* 2015;14(9):642-62 doi 10.1038/nrd4663.
26. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. *Cancer Res* 2001;61(24):8751-7.
27. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. *Cancer Res* 2005;65(21):9991-8 doi 10.1158/0008-5472.CAN-05-1630.
28. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. *Cancer Res* 2007;67(20):10038-46 doi 10.1158/0008-5472.CAN-07-0146.

29. Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. *Cancer Res* 2008;68(7):2071-5 doi 10.1158/0008-5472.CAN-07-6515.

30. Sathaiah M, Thirunavukkarasu P, O'Malley ME, Kavanagh MA,
5 Ravindranathan R, Austin F, et al. Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. *Cancer Gene Ther* 2012;19(3):192-201 doi 10.1038/cgt.2011.77.

31. Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, Thorne SH, Bartlett DL. Chemokine expression from oncolytic vaccinia virus enhances vaccine
10 therapies of cancer. *Mol Ther.* 2011 Apr;19(4):650-7. doi: 10.1038/mt.2010.312.

32. Liu Z, Ravindranathan R, Li J, Kalinski P, Guo ZS, Bartlett DL. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. *Oncoimmunology*. 2015 Oct 29;5(3):e1091554.

15 10. REFERENCES

1. United States Patent No. 6277368.
2. United States Patent No. 7208313.
3. United States Patent No. 7264820.
4. United States Patent No. 8506947
- 20 5. United States Patent Application Publication No. 2003/0031681.
6. United States Patent Application Publication No. 2003/0105054
7. United States Patent Application Publication No.2007/0154458
8. International Patent Application Publication no. WO 1999006544.
9. International Patent Application Publication No. WO 2003017944.
- 25 10. Bartlett DL et al., 2013, Oncolytic viruses as therapeutic cancer vaccines, *Molecular Cancer* 12:103-120.
11. Chiocca EA and Rabkin SD, 2014, *Cancer Immunol Res*; 2(4); 295–300.
12. Ferguson et al., “Chapter 11: Glycosylphosphatidyl Anchors” in Glycobiology, 2nd Edition, Varki et al., editors, Cold Spring Harbor Press, 2009.
- 30 13. Galian C et al., 2012, *J Biol. Chem.* 287 (2)):16399-16409.
14. Kaufman HL et al., 2015, *Nature Reviews Drug Discovery* 14:642–662.
15. Mayor S and Riezman H, 2004, *Nature Reviews Molecular Cell Biology* 5, 110-120.
16. McCart et al., 2001, *Cancer Research* 61:8751-8757.

17. Simmons D and Seed B, 1988, *Nature* 333:568-570.
18. Thorne S et al., 2007, *J. Clin. Invest.* 117:3350-3358.
19. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. *Front Oncol* (2014) 4:74. DOI: 10.3389/fonc.2014.00074.
20. Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. *Front Immunol* (2017) 8:555. DOI: 10.3389/fimmu.2017.00555.
21. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J Clin Oncol* (2015) 33:2780-8. DOI: 10.1200/JCO.2014.58.3377.
22. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat Rev Cancer* (2005) 5:263-74. DOI: nrc1586 [pii] 10.1038/nrc1586.

In addition to the various embodiments depicted and claimed, the disclosed subject matter is also directed to other embodiments having other combinations of the features disclosed and claimed herein. As such, the particular features presented herein can be combined with each other in other manners within the scope of the disclosed subject matter such that the disclosed subject matter includes any suitable combination of the features disclosed herein. The foregoing description of specific embodiments of the disclosed subject matter has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosed subject matter to those embodiments disclosed.

It will be apparent to those skilled in the art that various modifications and variations can be made in the systems and methods of the disclosed subject matter without departing from the spirit or scope of the disclosed subject matter. Thus, it is intended that the disclosed subject matter include modifications and variations that are within the scope of the appended claims and their equivalents.

Various references, patents and patent applications are cited herein, the contents of which are hereby incorporated by reference herein in their entireties.

WE CLAIM:

1. A method of treating a subject suffering from cancer, comprising:
 - (a) administering, to the subject, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer;
 - 5 (b) isolating the tumor-infiltrated T cells from the cancer of the subject;
 - (c) expanding the tumor-infiltrated T cells *ex vivo*; and
 - (d) transferring the expanded tumor-infiltrated T cells to the subject suffering from cancer.
2. The method of claim 1, wherein the oncolytic virus is a vaccinia virus.
- 10 3. The method of claim 1, wherein the oncolytic virus is a herpes simplex virus.
4. The method of claim 1, wherein the oncolytic virus is a recombinant vaccinia virus with an inactivating mutation of its thymidine kinase gene, vaccinia growth factor gene, or both.
- 15 5. The method of any of one claims 1-4, wherein the oncolytic virus comprises a nucleic acid encoding an immunomodulator molecule.
6. The method of any one of claims 1-4, wherein the oncolytic virus comprises a nucleic acid encoding a membrane-associated protein comprising an immunomodulator molecule.
- 20 7. The method of any one of claims 1-6, wherein the cancer is locally invasive.
8. The method of any one of claims 1-6, wherein the cancer is metastatic.
9. The method of any one of claims 1-8, wherein expanding the tumor-infiltrated T cells *ex vivo* comprises co-culturing the tumor-infiltrated T cells with
- 25 dendritic cells and cancer cells.
10. The method of any one of claims 1-9, wherein expanding the tumor-infiltrated T cells comprises culturing the tumor-infiltrated T cells with cytokines and/or agents.
11. The method of claim 10, wherein the cytokines and/or the agents comprise
- 30 one or more of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, IL-21, IL-23, IL-24, IL-27, IFN-alpha, IFN-alpha2, IFN-beta, or IFN-gamma, TNF-alpha, TNF-beta, and GM-CSF.

12. The method of any one of claims 1-11, wherein expanding the tumor-infiltrated T cells comprises culturing the tumor-infiltrated T cells with IL-2, IL-7, and/or GSK3b.

13. The method of any one of claims 1-12, wherein before transferring the
5 tumor-infiltrated T cells to the subject suffering from cancer, the subject suffering from cancer is treated with a cancer therapy.

14. The method of any one of claims 1-12, further comprising treating the subject suffering from cancer with a cancer therapy.

15. The method of any one of claims 1-12, further comprising providing to the
10 subject suffering from cancer with one or more exogenous cytokine and/or agent.

16. The method of any one of claims 1-12, further comprising providing to the subject suffering from cancer with exogenous IL-2, after transferring the tumor-infiltrated T cells.

17. The method of any one of claims 1-16, where the tumor-infiltrated cells
15 are transferred intraperitoneally.

18. The method of any one of claims 1-16, where the tumor-infiltrated cells are transferred intratumorally.

19. A method for generating tumor infiltrating oncolytic-virus induced T cells, comprising:

- 20 (a) administering, to a subject having a cancer, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer;
(b) isolating the tumor-infiltrated T cells from the cancer of the subject; and
(c) expanding the tumor-infiltrated T cells *ex vivo*.

20. The method of claim 19, wherein the oncolytic virus is a vaccinia virus.

25 21. The method of claim 19, wherein the oncolytic virus is a herpes simplex virus.

22. The method of claim 19, wherein the oncolytic virus is a recombinant vaccinia virus with an inactivating mutation of its thymidine kinase gene, vaccinia growth factor gene, or both.

30 23. The method of any one of claims 19-22, wherein the oncolytic virus comprises a nucleic acid encoding an immunomodulator molecule.

24. The method of any one of claims 19-22, wherein the oncolytic virus comprises a nucleic acid encoding a membrane-associated protein comprising an immunomodulator molecule.

25. The method of any one of claims 19-24, wherein the tumor-infiltrated T cells are expanded *ex vivo* in the presence of IL-2, IL-7, and/or GSK3b.

26. A method of treating a subject suffering from cancer, comprising administering to the subject one or more tumor infiltrating oncolytic-virus induced T cells
5 produced by the method of any one of claims 19-25.

27. An oncolytic virus encoding a membrane-associated protein comprising an immunomodulator molecule linked to an anchoring peptide.

28. An oncolytic virus comprising, in its genome, a nucleic acid encoding a membrane-associated protein comprising an immunomodulator molecule linked to an
10 anchoring peptide.

29. The oncolytic virus of claim 27 or 28, wherein the immunomodulator molecule is joined to the anchoring peptide via a linker peptide.

30. The oncolytic virus of any one of claims 27-29, wherein the oncolytic virus is a vaccinia virus.

31. The oncolytic virus of any one of claims 27-29, wherein the oncolytic virus is a recombinant vaccinia virus with an inactivating mutation of its thymidine kinase gene, vaccinia growth factor gene, or both.
15

32. The oncolytic virus of any one of claims 27-31, wherein the nucleic acid encoding the immunomodulatory molecule linked to the anchoring peptide is operably
20 linked to the p7.5 e/l promoter.

33. The oncolytic virus of any one of claims 27-31, wherein the nucleic acid encoding the immunomodulatory molecule linked to the anchoring peptide is operably linked to the pSe/l promoter.

34. The oncolytic virus of any one of claims 27-29, wherein the oncolytic
25 virus is a herpes simplex virus.

35. The oncolytic virus of any one of claims 27-29, wherein the oncolytic virus is an adenovirus.

36. The oncolytic virus of any one of claims 27-35, wherein the anchoring peptide comprises a GPI-anchor acceptor peptide.

37. The oncolytic virus of any one of claims 27-35, wherein the anchoring
30 peptide comprises a PD-L1 transmembrane domain.

38. The oncolytic virus of any one of claims 27-35, wherein the anchoring peptide is coupled to the immunomodulator molecule via linker.

39. The oncolytic virus of claim 38, wherein the linker is a flexible linker.

40. The oncolytic virus of claim 38, wherein the linker is a rigid linker.
41. The oncolytic virus of any one of claims 27-40, wherein the immunomodulator molecule is interleukin-2.
42. The oncolytic virus of any one of claims 27-40, wherein the immunomodulator molecule is interferon-gamma.
43. The oncolytic virus of any one of claims 27-40, wherein the immunomodulator molecule is tumor necrosis factor-alpha.
44. A therapeutic composition comprising the oncolytic virus of any one of claims 27-43, together with a physiologic buffer.
45. The therapeutic composition of claim 44, in lyophilized form.
46. A syringe comprising an effective amount of a therapeutic composition of claim 44.
47. A method of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus encoding an immunomodulator molecule.
48. The method of claim 47, wherein the immunomodulator molecule is interleukin-2.
49. A method of treating a subject suffering from a cancer, comprising administering, to the subject, an effective amount of an oncolytic virus according to any of claims 27-43.
50. The method of claim 47, 48 or 49, wherein the oncolytic virus is administered as a therapeutic composition.
51. The method of claim 47, 48 or 49, wherein the oncolytic virus is administered as a therapeutic composition according to claim 44 or 45.
52. The method of claim 47, 48 or 49, wherein the oncolytic virus is administered using the syringe of claim 46.
53. The method of any one of claims 47-52, wherein the cancer is locally invasive.
54. The method of any one of claims 47-52, wherein the cancer is metastatic.
55. The method of any one of claims 47-54, wherein the oncolytic virus is administered intratumorally.
56. The method of any one of claims 47-54, further comprising the administration of a therapeutically effective amount of an immunomodulatory agent.

57. The method of claim 56, wherein the immunomodulatory agent is an anti-PD-1 or an anti-PD-L1 antibody.

58. The method of any one of claims 47-57, further comprising an additional therapy.

5 59. The use of an oncolytic virus of any one of claims 27-43 for treating a subject having cancer.

60. The use of an oncolytic virus for generating tumor infiltrating oncolytic-virus induced T cells.


10 61. The use of tumor infiltrating oncolytic-virus induced T cells for treating a subject having cancer.

62. The use of claim 60 or 61, wherein the tumor infiltrating oncolytic-virus induced T cells are generated by a method comprising:

(a) administering, to a subject having a cancer, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer;

15 (b) isolating the tumor-infiltrated T cells from the cancer of the subject; and

(c) expanding the tumor-infiltrated T cells *ex vivo*.



2/45

A. Experimental scheme




FIG. 2A

B. Long-term survival of MC38-colon cancer-bearing mice treated on day 9:
Mice died due to toxicity of secreted IL-2 wDD-IL-2 treated group




FIG. 2B




FIG. 3A





FIG. 3B






FIG. 5B




FIG. 5A

6/45

A. Experimental scheme




FIG. 6A

B. Survival




FIG. 6B

7/45

A. Experimental scheme




FIG. 7A

B. Toxicity




FIG. 7B

8/45

A. Experimental Scheme




FIG. 8A

B. Survival

T-cell transfer of vvDD-IL2 induced T-cells




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B






FIG. 11C






FIG. 13













FIG. 14A








FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 17A




FIG. 17B




FIG. 17C




FIG. 17D




FIG. 18C




FIG. 18B




FIG. 18A




FIG. 18F




FIG. 18E




FIG. 18D




FIG. 18I

FIG. 18H

FIG. 18G




FIG. 18L

FIG. 18K

FIG. 18J




FIG. 18M




FIG. 18N




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D

24/45




FIG. 20




FIG. 21B




FIG. 21A

26/45




FIG. 22A




FIG. 22B




FIG. 22C




FIG. 22E




FIG. 22D




FIG. 23A

FIG. 23B




FIG. 23C

29/45




FIG. 24A




FIG. 24B





FIG. 25B



31/45




FIG. 26A






FIG. 26B



33/45




FIG. 28




FIG. 29B




FIG. 29A




FIG. 29C




FIG. 30




FIG. 30 continued




FIG. 30 continued




FIG. 31A





FIG. 31B

FIG. 31C






FIG. 32




FIG. 32 continued




FIG. 33A




FIG. 33B





FIG. 33C



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2018/016912

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

- a. ☐ forming part of the international application as filed:
☐ in the form of an Annex C/ST.25 text file.
☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13*ter*.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
☒ in the form of an Annex C/ST.25 text file (Rule 13*ter*.1(a)).
☐ on paper or in the form of an image file (Rule 13*ter*.1(b) and Administrative Instructions, Section 713).
2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2018/016912

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 7-18, 25, 26, 30-46, 49-59
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2018/016912

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C07K 14/47; C07K 14/52; C12N 7/01; C12N 15/09 (2018.01)

CPC - A61K 35/17; A61K 35/76; A61K 38/19; A61K 45/06; A61K 35/761; A61K 35/768; A61K 38/1764; A61K 38/1774; A61K 39/0011 (2018.02)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 424/93.2 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	US 2016/0000842 A1 (BAYLOR COLLEGE OF MEDICINE) 07 January 2016 (07.01.2016) entire document	47, 48, 60, 61 ----- 1-6, 19-24, 27-29, 62
Y	US 2010/0303714 A1 (KIRN) 02 December 2010 (02.12.2010) entire document	1-6, 19-24, 62
Y	PAN et al. "Cancer Immunotherapy Using a Membrane-bound Interleukin-12 With B7-1 Transmembrane and Cytoplasmic Domains," Molecular Therapy, 14 February 2012 (14.02.2012), Vol. 20, No. 5, Pgs. 927-937. entire document	6, 24, 27-29
A	LIU et al. "CXCL11-Armed Oncolytic Poxvirus Elicits Potent Antitumor Immunity and Shows Enhanced Therapeutic Efficacy," Oncolmunology, 29 October 2015 (29.10.2015), Vol. 5, No. 3, Article e1091554, Pgs. 1-10. entire document	1-6, 19-24, 27-29, 47, 48, 60-62
A	WO 2016/070136 A1 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY et al) 06 May 2016 (06.05.2016) entire document	1-6, 19-24, 27-29, 47, 48, 60-62
A	WO 2016/174200 A1 (PSIOXUS THERAPEUTICS LIMITED) 03 November 2016 (03.11.2016) entire document	1-6, 19-24, 27-29, 47, 48, 60-62
A	US 2016/0250267 A1 (UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION) 01 September 2016 (01.09.2016) entire document	1-6, 19-24, 27-29, 47, 48, 60-62



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 April 2018

Date of mailing of the international search report

10 MAY 2018

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774